Abstract
Dysfunction of the visceral tract has been considered for a long time to be the cause of diabetes mellitus. Bomskov (1910) reported severe diabetic symptoms in dogs after cannulation of the ductus lymphaticus. This observation, however, could not be confirmed in later experiments (Vogel 1963). Mehring and Minkowski (1890) noted polyuria, polydipsia, polyphagia, and severe glycosuria following removal of the pancreas in dogs. The final proof for the existence of a hormone in the pancreas was furnished by Banting and Best (1922) who could reduce the elevated blood sugar levels in pancreatectomized dogs by injection of extracts of the pancreatic glands. The role of the pituitary gland in development of diabetes has first been elucidated by Houssay (1930, 1931) in pancreatectomized dogs (Survey by Beyer and Schöffling 1986).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Banting FG, Best CH (1922) The internal secretion of the pancreas. J Lab Clin Med 7:251–266
Beyer J, Schöffling K (1968) Die Houssay-Präparation (Methodisches Vorgehen und Auswirkungen der Versuchsanordnung auf Stoffwechsel und endokrines System) in: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 745–761
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Houssay BA (1930) Le diabète pancréatique des chiens hypophysectomisés. Les troubles diabétiques chez les chiens privés d’hypophyse et de pancréas. Compt rend Soc Biol, Paris 105:121–126
Houssay BA, Biasotti A (1931) Pankreasdiabetes und Hypo- physe am Hund. Pflüger’s Arch ges Physiol 227:664–685
Sirek A (1968) Pancreatectomy and diabetes. in: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 727–743
Vogel HG (1963) Unpublished data von Mehring J, Minkowski 0 (1890) Diabetes mellitus nach Pankreasexstirpation. Arch exper Path Pharmakol 26: 371–387
Baily CC, Baily OT (1943) Production of diabetes mellitus in rabbits with alloxan. A preliminary report. J Am Med Ass 122:1165–1166
Bänder A, Pfaff W, Schmidt FH, Stork H, Schröder HG (1969) Zur Pharmakologie von HB 419, einem neuen, stark wirksamen oralen Antidiabeticum. Arzneim Forsch/Drug Res 19:1363–1372
Blum F, Schmid R (1954) Über den Einfluss der Konzentration auf den Ablauf des experimentellen Alloxandiabetes. Helv Physiol Acta 12:181–183
Brunschwig A, Allen JG, Goldner MG, Gomori G (1943) AIloxan. J Am Med Ass 122:966
Dunn JS, McLetchie NGB (1943) Experimental alloxan diabetes in the rat. Lancet 11:384–387
Frerichs H, Creutzfeldt W (1968) Diabetes durch BetaZytotoxine. In: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 811–840
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Goldner MG, Gomori G (1944) Studies on the mechanism of alloxan diabetes. Endocrinology 35:241–248
Heikkila RE, Barden H, Cohen G (1974) Prevention of alloxan-induced diabetes by ethanol administration. J Pharm Exp Ther 190:501–506
Katsumata K, Katsumata Y (1990) Effect of single administration of tolbutamide on the occurrence of alloxan diabetes in rats. Horm Metabol Res 22:192–193
Katsumata K, Katsumata Y, Ozawa T, Katsumata Jr (1993) Potentiating effect of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats. Horm Metab Res 25:125–126
Kodoma T, Iwase M, Nunoi K, Maki Y, Yoshinari M, Fujishima M (1993) A new diabetes model induced by neonatal alloxan treatment in rats. Diab Res Clin Pract 20: 183–189
Pincus IJ, Hurwitz JJ, Scott ME (1954) Effect of rate of injection of alloxan on development of diabetes in rabbits. Proc Soc Exp Biol Med 86:553–558
Tasaka Y, Inoue Y, Matsumoto H, Hirata Y (1988) Changes in plasma glucagon, pancreatic polypeptide and insulin during development of alloxan diabetes mellitus in dog. Endocrinol Japon 35:399–404
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Iwakiri R, Nagafuchi S, Kounoue E, Nakano S, Koga T, Nakayama M, Nakamura M. Niho Y (1987). Cyclosporin A enhances streptozocin induced diabetes in CD-1 mice. Experientia 43:324–327
Katsumata K, Katsumata K Jr, Katsumata Y (1992) Protective effect of diltiazem hydrochloride on the occurrence of alloxan-or streptozotocin-induced diabetes in rats. Horm Met Res 24:508–510
Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: A new model of diabetes mellitus. Science 133:415–417
Miller DL (1990) Experimental diabetes: Effect of streptozotocin on the golden Syrian hamster. Lab Anim Sci 40: 539–540
Rakieten N, Rakieten ML, Nadkarni MV (1963) Studies on the diabetogenic action of streptozotocin NSC-37917). Cancer Chemother Rep 29:91–102
Rossini AA, Like AA, Chick A, Appel MC, Cahill GF (1977) Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci, USA, 74:2485–2489
Tancrède G, Rousseau-Migneron S, Nadeau A (1983) Longterm changes in the diabetic state induced by different doses of streptozotocin in rats. Br J Exp Path 64:117–123
Bavelsky ZE, Zavyazkina TV, Moisev YS, Medvedev VI (1992) Zinc content in pancreatic islets in experimental diabetes induced by chelating agents. Patol Fiziol Eksp Ter 36:29–32
Caterson ID, Cooney GJ, Vanner MA, Nicks JL, Williams PF (1988) The activities of the pyruvate dehydrogenase complex and of acetyl-CoA carboxylase in various tissues in experimental obesity: tissue differences and insulin resistance. Diab Nutr Metab 1:65–70
Goldberg ED, Eshchenko VA, Bovt VD (1991) The diabetogenic and acidotropic effects of chelators. Exp Pathol 42: 59–64
Hansen WA, Christie MR, Kahn R, Norgard A, Abel I, Petersen AM, Jorgensen DW, Baekkeskov S, Nielsen JH, Lernmark A, Egeberg J, Richter-Olesen H, Grainger T, Kristensen JK, Brynitz S, Bilde T (1989) Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res 10:53–57
Maske H, Weinges K (1957) Untersuchungen über das Verhalten der Meerschweinchen gegenüber verschiedenen diabetogenen Noxen. Alloxan and Dithizon. Naunyn-Schmiedeerg’s Arch exper Path Pharmakol 230:406–420
Silva E, Hernandez L (1989) Goldthioglucose causes brain and serotonin depletion correlated with increased body weight. Brain Res 490:192–195
Stauffacher W, Lambert AE; Vecchio D, Renold AE (1967) Measurement of insulin activities in pancreas and serum of mice with spontaneous (“obese” and “New Zealand obese”) and induced (goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia 3:230–237
Martin TE, Young FG (1968) Experimental diabetes following growth hormone. In: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 763–770
Young FG (1945) Growth and diabetes in normal animals treated with pituitary (anterior lobe) diabetogenic extract. Biochem J 39:515–536
Abelove WA, Paschkis KE (1954) Comparison of the diabetogenic action of cortisone and growth hormone in different species. Endocrinology 55:637–654
Bellens R, Bastenie PA (1968) Experimental steroid diabetes. In: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 797–810
Hausberger FX, Ramsay AJ (1953) Steroid diabetes in guinea pigs. Effect of cortisone administration on blood-and urinary glucose, nitrogen excretion, fat deposition, and the islets of Langerhans. Endocrinology 53:423–435
Ingle DJ (1941) The production of glycosuria in the normal rat by means of 17-hydroxy-l1-dehydrocorticosterone. Endocrinology 29:649–652
Ingle DJ, Li CH, Evans HM (1946) The effect of adrenocorticotropic hormone on the urinary excretion of sodium, chloride, potassium, nitrogen and glucose in normal rats. Endocrinology 39:32–39
Arnim J, Grant RT, Wright PH (1960) Acute insulin deficiency provoked by single injections of anti-insulin serum. J Physiol (London) 153:131–145
Moloney PJ, Coval M (1955) Antigenicity of insulin: diabetes induced by specific antibodies. Biochem J 59:179–185
Wright PH (1968) Experimental insulin-deficiency due to insulin antibodies. In: 841–865. Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 841–865
Craighead J (1978) Current views on the etiology of insulin-dependent diabetes mellitus. New Engl J Med 299:1439–1445
Giron DJ, Patterson RR (1982) Effect of steroid hormones on virus-induced diabetes mellitus. Infect Immun 37:820–822
Giron DJ, Cohen SJ, Lyons SP, Trombley ML, Gould CL (1983) Virus-induced diabetes mellitus in ICR Swiss mice is age dependent. Infect Immun 41:834–836
Gould CL, McMannama KG, Bigley NJ, Giron DJ (1985) Virus-induced murine diabetes. Enhancement by immunosuppression. Diabetes 34:1217–1221
Vialettes B, Baume D, Charpin C, De Maeyer-Guignard J, Vague P (1983) Assessment of viral and immune factors in EMC virus-induced diabetes: effects of cyclosporin A and interferon. J Lab Clin Immunol 10:35–40
Yoon JW, McClintock PR, Onodera T, Notkins AL (1980) Virus-induced diabetes mellitus. XVII. Inhibition by a nondiabetogenic variant of encephalomyocarditis virus. J Exp Med 152:878–892
Ellerman K, Wroblewski M, Rabinovitch A, Like A (1993) Natural killer cell depletion and diabetes mellitus in the BB/Wor rat. Diabetologia 36:596–601
Gottlieb PA, Berrios JP, Mariani G, Handler ES, Greiner D, Mordes JP, Rossini AA (1990) Autoimmune destruction of islets transplanted into RT6-depleted diabetes-resistant BB/Wor rats. Diabetes 39:643–645
Hao L, Chan SM, Lafferty KJ (1993) Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 969:328–332
Kolb H, Burkart V, Appels B, Hanenberg H, Kantwerk-Funke G, Kiesel U, Funda J, Schraermeyer U, Kolb-Bachofen V (1990) Essential contribution of macrophages to islet cell destruction in vivo and in vitro. J Autoimmun 3 Suppl): 117–120
Lee KU, Pak CY, Amano K, Yoon JW (1988) Prevention of lymphocytic thyroiditis and insulitis in diabetes-prone BB rats by the depletion of macrophages. Diabetologia 31: 400–402
Lefkowith J, Schreiner G, Cormier J, Handler ES, Driscoll HK, Greiner D, Mordes JP, Rossini AA (1990) Prevention of diabetes in the BB rat by essential fatty acid deficiency. J Exp Med 171:729–743
Like AA, Butler L, Williams RM, Appel MC, Weringer EJ, Rossini AA (1982) Spontaneous autoimmune diabetes mellitus in the BB rat. Diabetes 31 (Suppl 1):7–11
Nakhooda AF, Like AA, Chappel CI, Murray FT, Marliss EB (1977) The spontaneously diabetic Wistar rat; metabolic and morphologic studies. Diabetes 26:100–112
Nakhooda AF, Like AA, Chappel CI, Wei CN, Marliss EB (1978) The spontaneously diabetic Wistar rat (the `BB“ rat). Studies prior to and during development of the overt syndrome. Diabetologia 14:199–207
Papaccio G, Mezzogiorno V (1989) Morphological aspects of glucagon and somatostatin islet cells in diabetic Bio Breeding and low-dose streptozotocin-treated Wistar rats. Pancreas 4:289–294
Pipeleers D, Pipeleers-Marichal M, Markholst H, Hoorens A, Klöppel G (1991) Transplantation of purified islet cells in diabetic BB rats. Diabetologia 34:390–396
Sima AAF (1984) Neuropathic and ocular complications in the BB-Wistar rat. In: Shafrir R, Reynold A (eds) Lesson from Diabetes, London, pp 447–453
Solomon SS, Deaton J, Harris G, Smoake JA (1989) Studies of insulin resistance in the streptozotocin diabetic and BB rat: Activation of low Km cAMP phosphodiesterase by insulin. Am J Med Sci 297:372–376
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Koizumi M, Shimoda I, Sato K, Shishido T, Ono T, Ishizuka J, Toyota T, Goto Y (1989) Effects of CAMOSTAT on development of spontaneous diabetes in the WBN/Kob rats. Biomed Res 10, Suppl 1:45–50
Nakama K, Shichinohe K, Kobayashi K, Naito K, Ushida O, Yasuhara K, Zobe M (1985) Spontaneous diabetes-like syndrome in WBN/Kob rats. Acta Diabetol Lat. 122: 335–342
Tsichitani M Saegusa T, Narama I, Nishikawa T, Gonda T (1985) A new diabetic strain of rat (WBN/Kob) Laboratory Animals 19:200–207
Cohen AM, Teitelbaum A, Saliternik R (1972) Genetics and diet as factors in the development of diabetes mellitus. Metabolism 21:235–240
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F (1993) Effect of dihydro-epiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. Diabetes 42:662–669
Alamzadeh R, Slonim AE, Zdanowicz MM (1993) Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 133:705–712
Bray GA (1977) The Zucker-fatty rat: A review. Fed Proc 36: 148–153
Clark JB, Palmer CJ, Shaw WN (1983) The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173:68–75
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558
Galante P, Maerker E, Scholz R, Rett K, Herberg L, Mosthaf L, Häring HU (1994) Insulin-induced translocation of GLUT 4 in skeletal muscle of insulin-resistant Zucker rats. Diabetologia 37:3–9
Kasim SE, Elovson J, Khilnani S, Almario RU, Jen KLC (1993) Effect of lovostatin on the secretion of very low density lipoproteins and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. Atherosclerosis 104: 147–152
Kava R, Greenwoof MRC, Johnson PR (1990) Zucker (fa/fa) rat. Ilar News 32:4–8
McCaleb ML, Sredy J (1992) Metabolic abnormalities of the hyperglycemic obese Zucker rat. Metabolism 41:522–525
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Vasselli JR, Flory T, Fried KS (1987) Insulin binding and glucose transport in adipocytes of acarbose-treated Zucker lean and obese rats. Int J Obesity 11:71–75
Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H (1993) Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75–80
Zucker LM (1965) Hereditary obesity in the rat associated with hyperlipidemia. Ann NY Acad Sci 131:447–458
Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z (1981) A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 30:1045–1050
Kava R, Peterson RG, West DB, Greenwood MRC (1990) Ilar News 32:9–13
Kava RA, West DB, Lukasik VA, Greenwood MRC (1989) Sexual dimorphism of hyperglycemia and glucose tolerance in Wistar fatty rats. Diabetes 38:159–163
Kobayashi M, Iwanshi M, Egawa K, Shigeta Y (1992) Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476–483
Madar Z, Omusky Z (1991) Inhibition of intestinal aglucosidase activity and postprandial hyperglycemia by aglucosidase inhibitors in fa/fa rats. Nutrit Res 11:10351046
Peterson RG, Little LA, Neel MA (1990) WKY fatty rat as a model of obesity and non-insulin dependent diabetes mellitus. Ilar News 32:13–15
Velasquez MT, Kimmel PL, Michaelis OE, IV (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Dumm CLAG, Semino MC, Gagliardino JJ (1990) Sequential changes in pancreatic islets of spontaneously diabetic rats. Pancreas 5:533–539
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Tarrés MC, Martinez SM, Liborio MM, Rabasa SL (1981) Diabetes mellitus en una Linea endocrinada de rata. Mende-liana 5:39–48
Koletsky S (1973) Obese spontaneous hypertensive rats — a model for study of arteriosclerosis. Exp Mol Pathol 19: 53–60
Koletsky S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80: 129–142
Velasquez MT, Kimmel PL, Michaelis OE,IV (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Adamo M, Shemer J, Aridor M, Dixon J, Carswell N, Bhathena SJ, Michaelis OE,IV, LeRoith D (1989) Liver insulin receptor tyrosine kinase activity in a model of type II diabetes mellitus and obesity. J Nutr 119:484–489
Hansen CT (1983) Two new congenic rat strains for nutrition and obesity research. Fed Proc 42:573
Hansen CT (1988) The development of the SRH/N- and LA/Ncp (corpulent) congenic rat strains. In: Hansen CT, Michaelis OE,IV (eds) New models of genetically obese rats for studies in diabetes, heart disease, and complications of obesity. Summaries of Workshop Papers and Current Bibliography. National Institutes of Health, Bethesda, MD, pp 7–10
McCune SA, Baker PB, Stills HF (1990) SHHF/Mcc-cp rat: a model of obesity, non-insulin-dependent diabetes, and congestive heart failure. Ilar News 32:23–27
Michaelis 0E, Hansen CT (1990) The spontaneous hypertensive/NIH corpulent rat: a new rodent model for the study of non-insulin dependent diabetes mellitus and its complications. Ilar News 32:19–22
Michaelis 0E, Patrick DH, Hansen A, Canry JJ, Werner RM, Carswell N (1986) Spontaneous hypertensive/NIH-corpulent rat. An animal model for insulin-independent diabetes mellitus (type II).Am J Pathol 123:398–400
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Berdanier CD (1974) Metabolic abnormalities in BHE rats. Diabetologia 10:691–695
Durand AMA, Fisher M, Adams M (1964) Histology in rats as influenced by age and diet. Arch Pathol 77. 268–277
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Nakamura M (1962) A diabetic strain of the mouse. Proc Jap Acad 38:348–352
Nakamura M, Yamada K (1967) Studies on a diabetic (KK) strain of the mouse. Diabetologia 3:212–221
Diani AR, Sawada GA, Zhang NY, Wyse BM, Connell CL, Vidmar TJ, Connell MA (1987) The KKAY mouse: a model for the rapid development of glomerular capillary basement membrane thickening. Blood Vessels 24:297–303
Hofmann CA, Edwards CW, Hillman RM, Colca JR (1992) Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 130:735–740
Iwatsuka H, Shino A, Suzouki Z (1970) General survey of diabetic features of yellow KK mice. Endocrinol Japon 17:23–35
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]2,4-thiazolidinediones. Arzneim Forsch/Drug Res 40:37–42
Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM (1992) Rapamycin prevents the onset of insulin dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 89:174–178
Charlton B, Bacelj A, Mandel TE (1988) Administration of silica particles or anti-Lyt2 antibody prevents 13-cell destruction in NOD mice given cyclophosphamide. Diabetes 37:930–935
Geisen K, Deutschländer H, Gorbach S, Klenke C, Zimmermann U (1990) Function of barium alginate-microencapsulated xenogenic islets in different diabetic mouse models. In: Shafrir E (ed) Frontiers in Diabetes Research. Lessons from Animal Diabetes III. Smith-Gordon, pp 142–148
Lee KU, Amano K, Yoon JW (1988) Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 37:989–991
Matsuba H, Jitsukawa T, Yamagata N, Uchida S, Watanabe H (1994) Establishment of rat glutamic acid decarboxylase (GAD)-reactive T-cell clones from NOD mice. Immunol Lett 42:101–103
Nicoletti F, Di Marco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, Meroni PL (1994) Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 24:1843–1847
Tochino Y (1984) Breeding and characteristics of a spontaneously diabetic non obese strain (NOD mouse) of mice. In: Shafrir E, Renold AE (eds) Lessons from Animal Diabetes. John Libbey, London, pp 93–98
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850–2859
Bleisch VR, Mayer J, Dickie MM (1952) Familial diabetes mellitus in mice associated with insulin resistance, obesity and hyperplasia of the islands of Langerhans. Am J Pathol 28:369–385
Coleman DL, Hummel KP (1973) The influence of genetic background on the expression of obese (ob) gene in the mouse. Diabetologia 9:287–293
Dickie MM (1962) New mutations. Mouse News Letter 27:37
Gill AM, Yen TI’ (1991) Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 48:703–710
Hellman B (1967) Some metabolic aspects of the obesehyperglycemic syndrome in mice. Diabetologia 3:222–229
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Ingalls AM, Dickie MM, Snell GT (1950) Obese, a new mutation in the house mouse. J Hered 14:317–318
Mayer J, Bates MW, Dickie MM (1951) Hereditary diabetes in genetically obese mice. Science 113:746–747
Sirek A (1968) Spontaneous hereditary diabetes in laboratory animals. in: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 715–726
Stauffacher W, Lambert AE; Vecchio D, Renold AE (1967) Measurement of insulin activities in pancreas and serum of mice with spontaneous (“obese” and “New Zealand obese”) and induced (goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia 3:230–237
Stein JM, Bewsher PD, Stowers JN (1970) The metabolism of ketones, triglyceride and monoglyceride in livers of obese hyperglycaemic mice. Diabetologia 6:570–574
Westman S (1968) Development of the obese-hyperglycaemic syndrome in mice. Diabetologia 4:141–149
Berglund O, Frankel BJ, Hellman B (1980) Development of the insulin secretory defect in genetically diabetic (db/db) mouse. Acta Endocrinol 87:543–551
Coleman DL, Hummel KP (1967) Studies with the mutation diabetes in the mouse. Diabetologia 3:238–248
Gardner K (1978) Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (C57BL/6J db/db and C57BL/KsJ db/db) Diabetologia 15: 59–63
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Lee SM (1982) The effect of chronic a-glycosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes 13: 249–254
Leiter EH, Coleman DL, Ingram DK, Reynold MA (1983) Influence of dietary carbohydrate on the induction of diabetes in C5BL/KsJ-db/db diabetes mice. J Nutr 113:184–195
Like AA, Lavine RL, Poffenbarger PL, Chick WI (1972) Studies on the diabetic mutant mouse. VI Evolution of glomerular lesions and associated proteinuria. Am J Pathol 66:193–224
Stearns SB, Benz CA (1978) Glucagon and insulin relationships in genetically diabetic (db/db) and streptozotocininduced diabetic mice. Horm Metab Res 10:20–33
Cahill GF, Jones EE, Lauris V, Steinke J, Soeldner JS (1967) Studies on experimental diabetes in the Wellesley hybrid mouse. II. Serum insulin levels and response of peripheral tissues. Diabetologia 3:171–174
Gleason RE, Lauris V, Soeldner JS (1967) Studies on experimental diabetes in the Wellesley hybrid mouse. III. Dietary effects and similar changes in a commercial Swiss-Hauschke strain. Diabetologia 3:175–178
Jones E (1964) Spontaneous hyperplasia of the pancreatic islets associated with glycosuria in hybrid mice. In: Brolin SE, Hellman B, Knutson H (eds) The structure and metabolism of pancreatic islets. Pergamon Press, Oxford, pp 189–191
Like AA, Jones EE (1967) Studies on experimental diabetes in the Wellesley hybrid mouse. IV. Morphologic changes in islet tissue. Diabetologia 3:179–187
Cofford OB, Davis CK (1965) Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand obese mice. Metabolism 14:271–280
Melez KA; Harrison LC, Gilliam JN, Steinberg AD (1980) Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes 29:835–840
Seemayer TA, Colle E (1980) Pancreatic cellular infiltrates in autoimmune-prone New Zealand black mice. Diabetologia 19:216–221
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Veroni MC, Proietto J, Larkins RG (1991) Insulin resistance in New Zealand obese mice. Diabetes 40:1480
Butler L (1967) The inheritance of diabetes in the Chinese hamster. Diabetologia 3:124–129
Gerritsen CG, Dulin WE (1967) Characterization of diabetes in the Chinese hamster. Diabetologia 3:74–78
Gerritsen GC (1982) The Chinese hamster as a model for the study of diabetes mellitus. Diabetes 31 (Suppl 1) 14–23
Gundersen K, Yerganian G, Lin BJ, Gagnon H, Bell F, McRae W, Onsberg T (1967) Diabetes in the Chinese hamster. Some clinical and metabolic aspects. Diabetologia 3:85–91
Luse SA, Caramia F, Gerritsen G, Dulin WE (1967) Spontaneous diabetes mellitus in the Chinese hamster: An electron microscopic study of the islets of Langerhans. Diabetologia 3:97–108
Malaisse W, Malaisse-Lagae F, Gerritsen GC, Dulin WE, Wright PH (1967) Insulin secretion in vitro by the pancreas of the Chinese hamster. Diabetologia 3:109–114
Meier H, Yerganian G (1961) Spontaneous diabetes mellitus in the Chinese hamster (Cricetulus griseus). II. Findings in the offspring of diabetic parents. Diabetes 10:12–18
Meier H, Yerganian G (1961) Spontaneous hereditary diabetes mellitus in the Chinese hamster (Cricetulus griseus). III. Maintenance of a diabetic hamster colony with the aid of hypoglycemic therapy. Diabetes 10:19–21
Meier H, Yerganian GA (1959) Spontaneous hereditary diabetes mellitus in Chinese hamster (Cricetulus griseus). I. Pathological findings. Proc Soc Exper Biol Med 100: 810–815
Shirai T, Welsh GW, Sims EAH (1967) Diabetes mellitus in the Chinese hamster. II. The evolution of renal glomerulopathy. Diabetologia 3:266–286
Sims EAH, Landau BR (1967) Diabetes mellitus in the Chinese hamster. I. Metabolic and morphologic studies. Diabetologia 3:115–123
Sirek A (1968) Spontaneous hereditary diabetes in laboratory animals. in: Pfeiffer EF (ed) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag, München. pp 715–726
Sirek OV, Sirek A (1967) The colony of Chinese hamsters of the C.H. Best institute. A review of experimental work. Diabetologia 3:65–73
Soret MG, Dulin WE, Matthew’s J, Gerritsen GC (1974) Morphologic abnormalities observed in retina, pancreas and kidney of diabetic Chinese hamsters. Diabetologia 10: 567–579
Brodoff BN, Penhos JC, Levine R, White R (1967) The effect of feeding and various hormones on the glucose tolerance of the sand rat (Psammomys obesus) Diabetologia 3:167–170
DeFronzo R, Miki E, Steinke J (1967) Diabetic syndrome in sand rats. Diabetologia 3:140–142
Hackel DB, Mikat E, Lebovitz HE, Schmidt-Nielsen K, Horton ES, Kinney TD (1967) The sand rat (Psammomys obesus) as an experimental animal in studies of diabetes mellitus. Diabetologia 3:130–134
Hackel DB, Schmidt-Nielson K, Haines HB, Miai E (1965) Diabetes mellitus in the sand rat (Psammomys obesus) - pathologic studies. Lab Invest 14:200–207
Kalderon B, Gutman A, Levy E, Shafrir E, Adler JH (1986) Characterization of stages in the development of obesity-diabetes syndrome in the sand rat (Psammomys obesus). Diabetes 35:717–724
Marquie G, Duhault J, Jacotot B (1984) Diabetes mellitus in sand rats (Psammomys obesus). Metabolic pattern during development of the diabetic syndrome. Diabetes 33: 438–443
Miki E, Like AA, Steinke J, Soeldner JS (1967) Diabetic syndrome in sand rats. Diabetologia 3:135–139
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes/Metab Rev 8:179–208
Pictet R, Orci L, Gonet AE, Rouiller Ch, Renold AE (1967) Ultrastructural studies of the hyperplastic islets of Langerhans of spiny mice (Acomys Cahirinus) before and during the development of hyperglycemia. Diabetologia 3: 188–211
Renold AE, Dulin WE (1967) Spontaneous diabetes in laboratory animals. Diabetologia 3:63–64
Shafrir E, Teitelbaum A, Cohen AM (1972) Hyperlipidemia and impaired glucose tolerance in Acomys cahirinus maintained on synthetic carbohydrate diets. Isr J Med Sci 8: 990–992
Velasquez MT, Kimmel PL, Michaelis OE (1990) Animal models of spontaneous diabetic kidney disease. FASEB J 4: 2850–2859
Wise PH, Weir BJ, Hirne JM, Forrest E (1972) The diabetic syndrome in the Tuco-Tuco (Ctenomis talarum). Diabetologia 8:165–172
Schaefer EM, Viard V, Morin J, Ferré P, Pénicaud L, Ramos P, Maika SD, Ellis L, Hammer RE (1994) A new transgenic mouse model of chronic hyperglycemia. Diabetes 43: 143–153
Biological Assay of Insulin. British Pharmacopoeia 1988, Vol. II, London, Her Majesty’s Stationary Office, pp A168—A170
Insulin assay. Rabbit blood-sugar method. United States Pharmacopoeia XXII. The National Formulary XVII, 1990. United States Pharmacopoeia) Convention, Inc., Rockville, MD, pp 1513–1514
Underhill LA, Dabbah R, Grady LT, Rhodes CT (1994) Alternatives to animal testing in the USP-NF: Present and future. Drug Devel Industr Pharmacy 20:165–216
USP 23 (1995) Design and analysis of biological assays. The United States Pharmacopeia. pp 1705–1715
USP 23 (1995) Insulin assay. The United States Pharmacopeia. pp 1716–1717
Wertbestimmung von Insulin. Deutsches Arzneibuch, 9. Aus- gabe 1986, Deutscher Apotheker Verlag Stuttgart, pp 50–52
Biological Assay of Insulin. British Pharmacopoeia 1988, Vol. II, London, Her Majesty’s Stationary Office, pp A168–A170
Eneroth G, Ahlund K (1970) A twin crossover method for bioassay of insulin using blood glucose levels in mice — a comparison with the rabbit method. Acta Pharm Suec 7: 457–462
Trethewey J (1989) Bio-assays for the analysis of insulin. J Pharm Biomed Anal 7:189–197
Wertbestimmung von Insulin. Deutsches Arzneibuch, 9. Aus- gabe 1986, Deutscher Apotheker Verlag Stuttgart, pp 50–52
Ball EG, Merrill MA (1961) A manometric assay of insulin and some results of the application of the method to sera and islet-containing tissue. Endocrinology 69:596–607
Basi NS, Thomaskutti KG, Pointer RH (1992) Regulation of glucose transport in isolated adipocytes by levamisole. Can J Physiol Pharmacol 70:1190–1194
Clancy BM, Czech MP (1990) Hexose transport stimulation and membrane redistribution of glucose transporter isoforms in response to cholera toxin, dibutyryl cyclic AMP, and insulin in 3T3–L1 adipocytes. J Biol Chem 265:12434–12443
Ditschuneit H, Chang SA, Pfeiffer M, Pfeiffer EF (1959) Über die Bestimmung von Insulin im Blute am epididymalen Fettanhang der Ratte mit Hilfe markierter Glukose. Klin Wschr. 37:1234–1239
Foley JE, Cushman SW, Salans LB (1978) Glucose transport in isolated rat adipocytes with measurement of L-arabinose uptake. Am J Physiol 234:E112–E119
Foley JE, Gliemann J (1981) Accumulation of 2-deoxyglucose against its concentration gradient in rat adipocytes. Biochim Biophys Acta 648:100–106
Frost SC, Lane MD (1985) Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3–L1 adipocytes. J Biol Chem 260:2646–2652
Gliemann J (1965) Insulin-like activity of dilute human serum assayed by an isolated adipose cell method. Diabetes 14: 643–649
Gliemann J (1967) Assay of insulin-like activity by the isolated fat cell method. II. The suppressible and non-suppressible insulin-like activity of serum. Diabetologia 3: 389–394
Gliemann J (1967) Insulin assay by the isolated fat cell method. I. Factors influencing the response to crystalline insulin. Diabetologia 3:382–388
Gliemann J, osterlind K, Vinten J. Gammeltoft S (1972) A procedure for measurement of distribution spaces in isolated fat cells. Biochim Biophys Acta 286:1–9
Green H, Kehinde 0 (1974) Sublines of mouse 3T3 cells that accumulate lipid. Cell 1:113–116
Humbel RE (1959) Messung der Serum — Insulin — Aktivität mit epididymalem Fettgewebe in vitro. Experientia (Basel) 15:256–258
Jacobs DB, Hayer GR, Lockwood DH (1987) Effect of chlorpropamide on glucose transport in rat adipocytes in the absence of changes in insulin binding and receptor-associated tyrosine kinase activity. Metabolism 36:548–554
Karnieli E, Zarnowski MJ, Hissin PJ, Simpson IA, Salans LB, Cushman SW (1981) Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. J Biol Chem 256:4772–3777
Kletzien RF, Foellmi LA, Harris PKW, Wyse BM, Clarke SD (1992) Adipocyte fatty acid-binding protein: Regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 42:558–562
Lamer AC, Fleming JW (1984) Hormone-sensitive adenylate cyclase. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research Vol I: Laboratory Methods. Part B. John Wiley and Sons, New York, pp 23–36
Lingsoe J (1961) Determination of the insulin-like activity in serum using rat epididymal adipose tissue. Scand J Clin Lab Invest 13:628–636
Maloff BL, Lockwood DH (1981) In vitro effects of a sulfonylurea on insulin action in adipocytes. J Clin Invest 68:85–90
Marshall S, Garvey WT, Geller M (1984) Primary culture of adipocytes. J Biol Chem 259:6376–6384
Martin DB, Renold AE, Dagenais YM (1958) An assay for in- sulin-like activity using rat adipose tissue. Lancet 11: 76–77
McKee] DW, Jarett L (1970) Preparation and characterization of a plasma membrane fraction from isolated fat cells. J Cell Biol 44:417–432
Moody AJ, Stan MA, Stan M (1974) A simple free fat cell bioassay for insulin. Horm Metab Res 6:12–16
Müller G, Korndörfer A, Saar K, Karbe-Thönges B, Fasold H, Müllner S (1994) 4’-Amino-benzamido-taurocholic acid selectively solubilizes glycosyl-phophatidylinositol-anchored membrane proteins and improves lipolytic cleavage of their membrane anchors by specific phospholipases. Arch Biochem Biophys 309:329–340
Müller G, Wied S (1993) The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42:1852–1867
Pillion DJ (1985) Differential effects of insulin, antibodies against rat adipocyte plasma membranes, and other agents that mimic insulin action in rat adipocytes. Metabolism 34: 1012–1019
Renold AE, Martin DB, Dagenais YM, Steinke J, Nickerson RJ, Lauris V (1960) Measurement of small quantities of insulin-like activity using rat adipose tissue. I. A proposed procedure. J Clin Invest 39:1487–1498
Rodbell M (1964) Metabolism of isolated fat cells. I. Effect of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375–380
Siess E, Teinzer A, Wieland 0 (1965) Eine vereinfachte Methode zur Insulinbestimmung im Serum. Diabetologia 1:201–207
Slater JDH, Samaan N, Fraser R, Stillman D (1961) Immunological studies with circulating insulin. Br Med J 1:1712–1715
Sönksen PH, Ellis JP, Lowy C, Rutherford A, Nabarro JDN (1965) Plasma insulin: a correlation between bioassay and immunoassay. Br Med J (1965 II):209–210
Spooner PM, Chernick SS, Garrison MM, Scow RO (1979) Insulin regulation of lipoprotein lipase activity and release in 3T3–L1 adipocytes. J Biol Chem 254:10021–10029
Steinke J, Miki E, Cahill GF (1965) Assay of crystalline insulin and of serum insulin-like activity of different species on adipose tissue of the rat, mouse and guinea pig. New Engl J Med. 273:1464–1467
Steinke J, Sirek A, Lauris V, Lukens FDW, Renold AE (1962) Measurement of small quantities of insulin-like activity with rat adipose tissue. III. Persistence of serum insulin-like activity after pancreatectomy. J Clin Invest 41:1699–1707
Towbin H, Staehelin T, Gordon, J. (1979) Electrophoretic transfer from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354
Traxinger RR; Marshall S (1989) Role of amino acids in modulating glucose induced desensitization of the glucose transport system. J Biol Chem 264:20910–20916
Van Putten JPM, Krans HMJ (1986) Characterization of the sulfonylurea-induced potentiation of the insulin response in cultured 3T3 adipocytes. Biochem Pharmacol 35:2141–2144
Whitesell RR, Gliemann J (1979) Kinetic parameters of 3–0methylglucose and glucose in adipocytes. J Biol Chem 254: 5276–5283
Wieland M, Brandenburg C, Brandenburg D, Joost HG (1990) Antagonistic effect of a covalently dimerized insulin derivative on insulin receptors in 3T3–L1 adipocytes. Proc Natl Acad Sci USA 87:1154–1158
Zuber MX, Wang SM, Thammavaram KV, Reed DK, Reed BC (1985) Elevation of the number of cell-surface insulin receptors and the rate of 2-deoxyglucose uptake by exposure of 3T3–L1 adipocytes to tolbutamide. J Biol Chem 260: 14045–14052
Assimacopoulos-Jeannet F, Cusin I, Greco-Perotto RM, Terrettaz J, Rohner-Jeanrenaud F, Zarjevski N, Jeanrenaud B (1991) Glucose transporters: structure, function, and regulation. Biochimie 73:76–70
Bahr M, von Holtey M, Müller G, Eckel J (1995) Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLU1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 136:2547–2553
Baldwin JM, Gorga JC, Lienhard GE (1981) The monosaccharide transporter of the human erythrocyte. J Biol Chem 256:3685–3689
Begum N, Draznin B (1992).The effect of streptozotocininduced diabetes on GLUT-4 phosphorylation in rat adipocytes. J Clin Invest 90:1254–1262
Cusin I, Terrettaz J, Rohner-Jeanrenaud F, Zarjevski N, Assimacopoulos-Jeannet F, Jeanrenaud B (1990) Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: a clue for increased fat depot and insulin resistance. Endocrinology 127:3246–3248
Ezaki O, Kasuga M, Akanuma Y, Takata K, Hirano H, FujitaYamaguchi Y, Kasahara M (1986) Recycling of the glucose transporter, the insulin receptor, and insulin in rat adipocytes. J Biol Chem 261:3295–3305
Galante P, Maerker E, Scholz R, Rett K, Herberg L, Mosthaf L, Häring HU (1994) Insulin-induced translocation of GLUT4 in skeletal muscle of insulin-resistant Zucker rats. Diabetologia 37:3–9
Gould GW, Holman GD (1993) The glucose transporter family: structure, function and tissue-specific expression. Biochem J 295:329–341
Hofmann C, Lorenz K, Colca JR (1991) Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinol 129:1915–1925
Jacobs DB, Hayes GR, Lockwood DHl (1989) In vitro effect of sulfonylurea on glucose transport and translocation of glucose transporters in adipocytes from streptozocininduced diabetic rats. Diabetes 38:205–211
Jacobs DB, Jung CY (1985) Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes. J Biol Chem 260:2593–2596
James DE, Strube M, Mueckler M (1989). Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature 338:83–87
Klip A, Marette A (1992) Acute and chronic signals controlling glucose transport in skeletal muscle. J Cell Biochem 48:51–60
Klip A, Paquet MR (1990) Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care 13:228–243
Klip A, Ramlal T, Young DA, Holloszy JO (1987) Insulin-induced translocation of glucose transporters in rat hind-limb muscles. FEBS Lett 224:224–230
Laurie SM, Cain CC, Lienhard GE, Castle JD (1993) The glucose transporter GLUT4 and secretory membrane proteins (SCAMPs) colocalize in rat adipocytes and partially segregate during insulin stimulation. J Biol Chem 268:1911019117
Matthei S, Hamann A, Klein HH, Benecke H, Kreymann G, Flier JS, Greten H (1991) Association of metformin’s effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 40:850–857
Matthei S, Trost B, Hammann A, Kausch C, Benecke H, Greten H, Höppner W, Klein HH (1995) The effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT4 glucose transport systems in rat adipocytes. J Endocrinol 144:347–357
Mühlbacher C, Karnieli E, Schaff P, Obermaier B, Mushack J, Rattenhuber E, Häring HU (1988) Phorbol esters imitate in rat fat-cells the full effect of insulin on glucose-carrier translocation, but not on 3-O-methylglucose-transport activity. Biochem J 249:865–870
Müller G, Wied S (1993) The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42:1852–1867
Rampal AL, Jhun BH, Kim S, Liu H, Manka M, Lachaal M, Spangler RA, Jung CY (1995) Okadaic acid stimulates glucose transport in rat adipocytes by increasing the externalization rate constant of GLUT4 recycling. J Biol Chem 270: 3938–3943
Reusch JEB, Sussman KE, Draznin B (1993) Inverse relationship between GLUT-4 phosphorylation and its intrinsic activity. J Biol Chem 268:3348–3351
Simpson IA, Yver DR, Hissin PJ, Wardzala LJ, Karnieli E, Salans LB, Cushman SW (1983) Insulin-stimulated translocation of glucose transporters in the isolated rat adipose tissue cells: characterization of subcellular fractions. Biochim Biophys Acta 763:393–407
Towbin H, Staehelin T, Gordon, J. (1979) Electrophoretic transfer from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354
Honnor RC, Dhillon GS, Londos C (1985) cAMP dependent protein kinase and rat adipocytes. J Biol Chem 260:15122–15129
Kono T, Robinson FW, Sarver JA (1975) Insulin-sensitive phosphodiesterase. Its localization, hormonal stimulation, and oxidative stabilization. J Biol Chem 250:7826–7835
Müller G, Wied S, Wetekam EM, Crecelius A, Punter J (1994) Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas glimiperide and glibenclamide, is correlated with modulations of the cAMP regulatory cycle. Biochem Pharmacol 48:985–996
Müller HK, Kellerer M, Ermel B, Mühlhöfer A, ObermaierKusser B, Vogt B, Häring HU (1991) Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase in rat fat cells. Diabetes 40:1440–1448
Okuno S, Inaba M, Nishizawa Y, Inoue A, Morii H (1988) Effect of tolbutamide and glyburide on cAMP-dependent protein kinase activity in rat liver cytosol. Diabetes 37:857–861
Osegawa M, Makino H, Kanatsuka A, Kumagai A (1982) Effects of sulfonylureas on membrane-bound low Km cyclic AMP phosphodiesterase in rat fat cells. Biochim Biophys Acta 721:289–296
Roskoski R (1983) Assays of protein kinase. Meth Enzymol 99:3–6
Saltiel AR, Steigerwalt RW (1985) Purification of putative insulin-sensitive cAMP phosphodiesterase or its catalytic domain from adipose tissue. Diabetes 35:698–704
Solomon SS, Deaton J, Shankar TP, Palazzolo M (1986) Cyclic AMP phosphodiesterase in diabetes. Effect of glyburide. Diabetes 35:1233–1236
Sooranna SR, Saggerson ED (1976) Interactions of insulin and adrenaline with glycerol phosphate acylation processes in fat cells from rat. FEBS Lett 64:36–39
Vila MDC, Milligan G, Standaert ML, Farese RV (1990) Insulin activates glycerol-3-phosphate-acyltransferase (de novo phosphatidic acid synthesis) through a phospholipidderived mediator. Apparent involvement of Gia and activation of a phospholipase C. Biochem 29:8735–8740
Wieland 0 (1974) Glycerin UV-Methode. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse. Verlag Chemie Weinheim, pp 1448–1453
Araki E, Lipes MA, Patti ME, Brüning JC, Haag III B, Johnson RS, Kahn CR (1994) Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186–190
Berti L, Mosthaf L, Kroder GF, Kellerer M, Tippmer S, Mushack J, Seffer E, Seedorf K, Häring H (1994) Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase. J Biol Chem 269:3381–3386
DeMeyts P, Christoffersen CT, Ursks B, Ish-Shalom D, Sacerdote-Sierra N, Drejer K, Schäffer L, Shymko RM, Naor D (1993) Insulin’s potency as a mitogen is determined by the half-life of the insulin-receptor complex. Exp Clin Endocrinol 101:22–23
Myers MG, Sun XJ, White MF (1994) The IRS-1 signaling system. Trends Biochem Sci 19:289–293
Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci PG (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93–104
Pronk GJ, McGlade J, Pelicci G, Pawson T, Bos JL (1993) Insulin-induced phosphorylation of the 46- and 52-kDA Shc proteins. J Biol Chem 268:5748–5753
Quon MJ, Butte AT, Zarnowski MI, Sesti G, Cushman SW, Taylor SI (1994) Insulin receptor substrate 1 mediates the stimulatory effect of insulin on GLUT4 translocation in transfected rat adipose cells. J Biol Chem 269:27920–27924
Sasaoka T, Draznin B, Leitner JW, Langlois WJ, Olefsky JM (1994) Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21’°s-GPT formation. J Biol Chem 269: 10734–10738
Sun XJ, Miralpeix M, Myers MG, Glasheen EM, Backer JM, Kahn CR, White MF (1992) Expression and function of IRS-1 in insulin signal transmission. J Biol Chem 267:22662–22672
Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horokoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182–186
Tanti JF, Grémeaux T, Van Obberghen E, Le MarchandBrustel Y (1994) Serine/threonine phosphorylation of insulin substrate 1 modulates insulin receptor signaling. J Biol Chem 269:6051–6057
White MF, Maron R, Kahn RC (1985) Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318:183–186
Yonazawa K, Ando A, Kaburagi Y, Yamamoto-Honda R, Kitamura T, Hara K, Nakafuku M, Okabayashi Y, Kadowaki T, Kaziro Y, Kasuga M (1994) Signal transduction pathways from insulin receptor to ras. Analysis by mutant insulin receptors. J Biol Chem 269:4634–4640
Bordier C (1981) Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 256:1604–1607
Chan BL, Lisanti MP, Rodriguez-Boulan E, Saltiel AR (1988) Insulin-stimulated release of lipoprotein lipase by metabolism of its phosphatidinylinositol anchor. Science 241: 1670–1672
Cross GAM (1990) Glycolipid anchoring of plasma membrane proteins. Ann Rev Cell Biol 6:1–39
Ferguson MAJ (1991) Lipid anchors on membrane proteins. Curr Opin Struct Biol 1:522–529
Ferguson MAJ, Williams AF (1988) Cell-surface anchoring of proteins via glycosyl-phophatidylinositol structures. Ann Rev Biochem 57:285–320
Lamer J (1988) Insulin-signaling mechanisms. Lessons from the old testament of glycogen metabolism and the new testament of molecular biology. Diabetes 37:262–275
Lawrence JC, Hiken JF, Inkster M, Scott CW, Mumby MC (1986) Insulin stimulates the generation of an adipocyte phosphoprotein that is isolated with a monoclonal antibody against the regulatory subunit of bovine heart cAMPdependent protein kinase. Proc Nat1 Acad Sci USA 83: 3649–3653
Lewis KA, Garigapati VR, Zhou C, Roberts MF (1993) Substrate requirements of bacterial phosphatidinylinositolspecific phospholipase C. Biochem 32:8836–8841
Lisanti MP, Darnell JC, Chan BL, Rodriguez-Boulan E, Saltiel AR (1989) The distribution of glycosyl-phophatidylinositol anchored proteins is differentially regulated by serum and insulin. Biochem Biophys Res Comm 164:824–832
Low MG (1989) The glycosyl-phophatidylinositol anchor of membrane proteins. Biochim Biophys Acta 988:427–454
Low MG (1990) Degradation of glycosyl-phophatidylinositol anchors by specific phospholipases. In: Turner AJ (ed) Molecular and Cell Biology of Membrane Proteins. Glycolipid Anchors of Cell-surface Proteins. Ellis Horwood, New York, pp 35–63
Low MG, Saltiel AR (1988) Structural and functional roles of glycosyl-phophatidylinositol in membranes. Science 239: 268–275
Low MG, Stiernberg J, Waneck GL, Flavell RA, Kincade PW (1988) Cell-specific heterogeneity in sensitivity of phosphatidinylinositol-anchored membrane antigens to release by phopsholipase C. J Immunol Meth 113:101–111
Marshall S, Garvey WT, Geller M (1984) Primary culture of adipocytes. J Biol Chem 259:6376–6384
Muller G, Bandlow W (1991) A cAMP binding ectoprotein in the yeast Saccharomyces cerevisiae. Biochemistry 30: 10181–10190
Muller G, Dearey EA, Punter J (1993) The sulfonylurea drug, glimepiride, stimulates release of glycosylphophatidylinositol-anchored plasma membrane proteins from 3T3 adipocytes. Biochem J 289:509–521
Muller G, Korndörfer A, Saar K, Karbe-Thönges B, Fasold H, Milliner S (1994) 4’-Amino-benzamido-taurocholic acid selectively solubilizes glycosyl-phophatidylinositol-anchored membrane proteins and improves lipolytic cleavage of their membrane anchors by specific phospholipases. Arch Biochem Biophys 309:329–340
Muller G, Wied S, Wetekam EM, Crecelius A, Punter J (1994) Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas glimiperide and glibenclamide, is correlated with modulations of the cAMP regulatory cycle. Biochem Pharmacol 48:985–996
Pryde JG, Phillips JH (1986) Fractionation of membrane proteins by temperature-induced phase separation in Triton X114. Biochem J (1986) 233.525–533
Romero G, Luttrell L, Rogol A, Zeller K, Hewlett E, Larner J (1988) Phophatidylinositol-glycan anchors of membrane proteins: Potential precursors of insulin mediators. Science 240:509–512
Saltiel AR, Cuatrecasas P (1986) Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid. Proc Natl Acad Sci USA 83:5793–5797
Satiel AR (1990) Second messengers of insulin action. Trends Endocrinol Metab 1:158–163
Thomas JR, Dwek RA, Rademacher TW (1990) Structure, biosynthesis and function of gylcosylphosphatidinylinositols. Biochem 29:5413–5422
Altan N, Altan VM, Mikolay L, Lamer J, Schwartz CFW (1985) Insulin-like and insulin-enhancing effects of the sulfonylurea glyburide on rat adipose tissue glycogen synthase. Diabetes 34:281–286
Antoniades HN (1961) Studies on the state of insulin in blood: The state and transport of insulin in blood. Endocrinology 68:7–16
Chen-Zion M, Bassukevitz Y, Beitner R (1992) Sequence of insulin effects on cytoskeletal and cytosolic phosphofructokinase, glucose 1,6-biphosphate and fructose 2,6-biphosphate levels, and the antagonistic action of calmodulin inhibitors, in diaphragm muscle. Int J Biochem 24:1661–1667
Geiger R, Geisen K, Summ HD (1982) Austausch von A1Glycin in Rinderinsulin gegen L- und D-Tryptophan. Hoppe Seyler’s Z Physiol Chem 363:1231–1239
Groen J, Kamminga CE, Willebrands AF, Blickman JR (1952) Evidence for the presence of insulin in blood serum. A method for the approximate determination of the insulin content of blood. J Clin Invest 31:97–106
Guinovart JJ, Salavert A, Massagué J, Ciudad CJ, Salsas E, Itarte E (1979) Glycogen synthase: A new activity ratio assay expressing a high sensitivity to the phosphorylation state. FEBS Lett 106:284–288
Hothersall JS, Muirhead RP, Wimalawansa S (1990) The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm. Biochem Biophys Res Commun 169:451–454
Ishizuka T, Cooper DR, Hernandez H, Buckley D, Standaert M, Farese RV (1990) Effects of insulin on diacylglycerolprotein kinase C signaling in rat diaphragm and soleus muscle and relationship to glucose transport. Diabetes 39: 181–190
Lowry OH, Passonneau JV (1972) A flexible system of enzymatic analysis. Chapter 9: A collection of metabolite assays. Academic Press, New York, pp 174–177
Moody Ai, Felber JP (1964) A diaphragm bioassay for the measurement of total `insulin-like activity’ and of ‘antigenic insulin’ in serum. Experientia 20:105–108
Müller G, Wied S, Wetekam EM, Crecelius A, Punter J (1994) Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas glimiperide and glibenclamide, is correlated with modulations of the cAMP regulatory cycle. Biochem Pharmacol 48:985–996
Oron Y, Lamer J (1979) A modified rapid filtration assay of glycogen synthase. Anal Biochem 94:409–410
Pletscher A, Gey KF (1957) Über die Wirkung blutzuckersenkender Sulfonylharnstoffe auf das isolierte Rattenzwerchfell. Experientia 13:447–449
Randle PJ (1954) Assay of plasma insulin activity by the rat diaphragm method. Br Med J 1: 1237–1240
Robinson KA, Boggs KP, Buse MG (1993) Okadaic acid, insulin, and denervation effects on glucose and amino acid transport and glycogen synthesis in muscle. Am J Physiol; Endocrinol Metab 265:E36–E43
Smith RL, Lawrence JC (1984) Insulin action in denervated rat hemidiaphragm. J Biol Chem 259:2201–2207
Standing VF, Foy JM (1970) The effect of glibenclamide on glucose uptake in the isolated rat diaphragm. Postgrad Med J, Dec Suppl 16–20
Vallance-Owen J, Hurlock B (1954) Estimation of plasma insulin by the rat diaphragm method. Lancet 268:68–70
Valiance-Owen J, Wright PH (1960) Assay of insulin in blood. Physiol Rev 40:219–244
Willebrands AF, v.d. Geld H, Groen J (1958) Determination of serum insulin using the isolated rat diaphragm. The effect of serum dilution. Diabetes 7:119–124
Wright PH (1957) Plasma-insulin estimation by the rat diaphragm method. Lancet 11, 621–624
Freedlender AE, Vandenhoff GE, Macleod MS, Malcolm RR (1984) Radioimmunoassay of insulin. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research, Vol I: Laboratory Methods, Part B., John Wiley and Sons, New York, pp 295–305
Grodsky GM, Forsham PH (1960) An immunochemical assay of total extractable insulin in man. J Clin Invest 39:1070–1079
Hales CN, Randle PJ (1963) Immunoassay of insulin with insulin-antibody precipitate. Biochem J 88:137–146
Melani F, Lawecki J, Bartelt KM, Pfeiffer EF (1967) Immunologisch nachweisbares Insulin (IMI) bei Stoffwechselgesunden, Fettsüchtigen und adipösen Diabetikern nach intravenöser Gabe von Glukose, Tolbutamid und Glucagon. Diabetologia 3:422–426
Morgan CR, Lazarow A (1963) Immunoassay of insulin: Two antibody system. Plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 12:115–126
Starr JI, Horwitz DL, Rubenstein AH, Mako ME (1979) Insulin, proinsulin and C-peptide. In: Jaffe BM, Behrman HR (eds) Methods of Hormone Radioimmunoassay, 2nd ed., Academic Press, New York, pp 613–642
Yalow R, Black H, Villazon M, Berson SA (1960) Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 9:356–362
Yalow RS, Berson SA (1960) Immunoassay of endogenous plasma insulin in man. J Clin Invest 39:1157–1175
Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Amqvist JH (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313
Bremner M, Weiland M, Becker W, Müller-Wieland D, Streicher R, Fabry M, Joost HG (1993) Heterogeneity of insulin receptors in rat tissues as detected with the partial agonist B29,B29’-suberoyl-insulin. Molec Pharmacol 44: 271–276
Burke GT, Chantey JD, Okada Y, Cosmatos A, Ferderigos N, Katsoyannis PG (1980) Divergence of the in vitro biological activity and receptor binding affinity of a synthetic insulin analogue, [21-asparaginamide-Alnsulin. Biochemistry 19:4547–4556
DeMeyts P (1976) Insulin and growth hormone receptors in human cultured lymphocytes and peripheral blood monocytes. In: Blecher M (ed) Methods in Receptor Research. Part I, Marcel Dekker Inc., New York and Basel, pp 301–383
DeMeyts P, Bianco AR, Roth J (1976) Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 251:1877–1888
Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488–1495
Freychet P (1976) Insulin receptors. In: Blecher M (ed) Methods in Receptor Research, Part II, Marcel Dekker, Inc., New York and Basel, pp 385–428
Gammeltoft S (1984) Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev 64: 1321–1378
Gammeltoft S (1988) Binding properties of insulin receptors in different tissues. In: Insulin Receptors, Part A: Methods for the Study of Structure and Function. Alan R. Liss, Inc., pp 15–27
Gavin III JR, Kahn CR, Gorden P, Roth J, Neville DM (1975) Radioreceptor assay of insulin: Comparison of plasma and pancreatic insulins and proinsulins. J Clin Endocr Metab 41:438–445
Häring HU (1991) The insulin receptor: signalling mechanisms and contribution to the pathogenesis of insulin resistance. Diabetologia 34:848–861
Hjollund E (1991) Insulin receptor binding and action in human adipocytes. Dan Med Bull 38:252–270
Hollenberg MD, Cuatrecasas P (1976) Methods for the biochemical identification of insulin receptors. In: Blecher M (ed) Methods in Receptor Research, Part II, Marcel Dekker, Inc., New York and Basel, pp 429–477
Hurrell DG, Pedersen O, Kahn CR (1989) Alteration in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology 125:2454–2462
Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Häring H (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447–453
Klein HH, Freidenberg GR, Kladde M, Olefsky JM (1986) Insulin activation of insulin receptor tyrosine kinase in intact rat adipocytes. J Biol Chem 261:4691–4697
Koch R, Weber U (1981) Partial purification of the solubilized insulin receptor from rat liver membranes by precipitation with concanavalin A. Hoppe-Seyler’s Z Physiol Chem 362:347–351
Kurose T, Pashmforoush M, Yoshimasa Y, Carroll R, Schwartz GP, Thompson Burke G, Katsoyannis PG, Steiner DF (1994) Cross-linking of a B25 azidophenylalanine insulin derivative to the carboxy-terminal region of the a-subunit of the insulin receptor. J Biol Chem 269:29190–29197
Levy JR, Belsky M (1990) Down-regulated insulin receptors in HepG2 cells have an altered intracellular itinerary. Am J Med Sci 299:302–308
Markussen J, Halstram, Wiberg FC, Schaffer L (1991) Immobilized insulin for high capacity affinity chromatography of insulin receptors. J Biol Chem 266:18814–18818
Müller HK, Kellerer M, Ermel B, Mühldorfer A, ObermaierKusser B, Vogt B, Häring HU (1991) Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes 40:1440–1447
Nenoff P, Remke H, Müller F, Arndt T, Mothes T (1993) In vivo assessment of insulin binding in different organs of growing and adult glutamate-induced obese rats. Exp Clin Endocrinol 101:215–221
Olefsky JM (1976) Decreased insulin binding to adipocytes and circulating monocytes from obese subjects. J Clin Invest 57:1165–1172
Olichon-Berthe C, Hauguel-De Mouzon S, Péraldi P, Van Obberghen E, Le Marchand-Brustel Y (1994) Insulin receptor dephosphorylation by phosphotyrosine phosphatases obtained from insulin-resistant obese mice. Diabetologia 37: 56–60
Pedersen O, Hjollund E, Beck-Nielsen H, Lindskov HO, Sonne O, Gliemann J (1981) Insulin receptor binding and receptor-mediated insulin degradation in human adipocytes. Diabetologia 20:636–641
Pedersen O, Hjollund E, Linkskov HO (1982) Insulin binding and action on fat cells from young healthy females and males. Am J Physiol 243:E158—E167
Podlecki DA, Frank BH, Olefsky JM (1984) In vitro characterization of human proinsulin. Diabetes 33:111–118
Podskalny JM, Takeda S, Silverman RE, Tran D, Carpentier JL, Orci L, Gorden P (1985) Insulin receptors and bioresponses in a human liver cell line (Hep G-2) Eur J Biochem 150:401–407
Ribel U, Hougaard P, Drejer K, Sorensen AR (1990) Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies. Diabetes 39:1033–1039
Robertson DA, Singh BM, Hale PJ, Jensen I, Nattrass M (1992) Metabolic effects of monomeric insulin analogues of different receptor affinity. Diabet Med 9:240–246
Schäffer L, Kjeldsen T, Andersen AS, Wiberg FC, Larsen UD, Cara JF, Mirmira RG, Nakagawa SH, Tager HS (1993) Interaction of a hybrid insulin/insulin-like growth factor-I analog with chimeric insulin/type I insulin-like growth factor receptors. J Biol Chem 268:3044–3047
Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A (1993) Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 268:1087–1094
Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B 10-aspartic acid]insulin(human). Proc Natl Acad Sci USA 84:6408–6411
Standaert ML, Schimmel SD, Pollet RI (1984) The development of insulin receptors and responses in the differentiating nonfusing muscle cell line BC3H-1. J Biol Chem 259:2337–2345
Volund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Sorensen AR (1991) In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 8:839–847
Weiland M, Brandenburg C, Brandenburg D, Joost HG (1990) Antagonistic effects of a covalently dimerized insulin derivative on insulin receptors in 3T3–L1 adipocytes. Proc Natl Acad Sci USA 87:1154–1158
Whitcomb DC, O’Dorisio TM, Cataland S, Nishikawara MT (1985 a) Theoretical basis for a new in vivo radioreceptor assay for polypeptide hormones. Am J Physiol 249 (Endocrinol Metab 12) E555–E560
Whitcomb DC, O’Dorisio TM, Cataland S, Shetzline MA, Nishikawara MT (1985 b) Identification of tissue insulin receptors. Am J Physiol 249 (Endocrinol Metab 12) E61–E567
Zeuzem S, Stahl E, Jungmann E, Zoltobrocki M, Schöffling K, Caspary WF (1990) In vitro activity of biosynthetic human diarginylinsulin. Diabetologia 33:65–71
Zeuzem S, Taylor R, Agius L, Albisser AM, Alberti KGMM (1984) Differential binding of sulphated insulin to adipocytes and hepatocytes. Diabetologia 27:184–188
Biological assay of glucagon. British Pharmacopoeia 1988, Vol II, London, Her Majesty’s Stationary Office, pp A70–A171
Harris V, Faloona GR, Unger RH (1978) Glucagon. In: Jaffe BM, Behrman HR (eds) Methods of Hormone Radioimmunoassay. Second edition, Academic Press New York, San Francisco, London, pp 643–656
Unger RH, Eisentraut AM, McCall MS, Keller S, Lanz HC, Madison LL (1959) Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 102:621–623
von Schenk H (1984) Radioimmunoassay of glucagon. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research, Vol I: Laboratory Methods, Part A, John Wiley and Sons, New York, pp 327–345
Goldstein St, Blecher M (1976) Isolation of glucagon receptor proteins from rat liver plasma membranes. In: Blecher M (ed) Methods in Receptor Research, Part I, Marcel Decker, Inc., New York and Basel, pp 119–142
Hagopian WA, Tager HS (1983) Receptor binding and cell-mediated metabolism of [’25I]monoiodoglucagon by isolated hepatocytes. J Biol Chem 259:8986–8993
Hruby VJ, Gysin B, Trivedi D, Johnson DG (1993) New glucagon analogues with conformational constrictions and altered amphiphilicity: Effects on binding, adenylate cyclase and glycogenolytic activities. Life Sci 52:845–855
Ishibashi H, Cottam GL (1978) Glucagon-stimulation of pyru- vate kinase in hepatocytes. J Biol Chem 253:8767–8771
Jorgensen KH, Larsen UD (1972) Purification of 1251-glucagon by ion exchange chromatography. Horm Metab Res 4: 223–224
Lin ME, Wright DE, Hruby VL, Rodbell M (1985) Structure-function relationships in glucagon: properties of highly purified des-his’-monoiodo-, and [des-asn2,thr29](homoserine lactone) glucagon. Biochemistry 14:1559–1563
McVittie LD, Gurd RS (1989) Stabilization of soluble active rat liver glucagon receptor. Arch Biochem Biophys 273:254–263
Neville DM (1968) Isolation of an organ specific protein antigen from cell-surface membrane of rat liver. Biochim Biophys Acta 154:540–552
Pohl SL (1976) The glucagon receptor in plasma membranes prepared from rat liver. In: Blecher M (ed) Methods in Receptor Research, Part I, Marcel Decker, Inc., New York and Basel, pp 159–174
Pohl SL, Birnbaumer L, Rodbell M (1971) The glucagonsensitive adenyl cyclase system in plasma membranes of rat liver. J Biol Chem 246:1849–1856
Sato N, Irie M, Kajinuma H, Suzuki K (1990) Glucagon inhibits insulin activation of glucose transport in rat adipocytes mainly through a postbinding process. Endocrinol 127: 1072–1077
Unson CG, McDonald D, Ray K, Durrah TL, Merrifield RB (1991) Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J Biol Chem 266:2763–2766
Wright DE, Rodbell M (1979) Glucagon,.6binds to the glucagon receptor and activates hepatic adenylate cyclase. J Biol Chem 254:268–269
Zechel Ch, Trivedi D, Hruby VJ (1991) Synthetic glucagon agonists and antagonists. Int J Peptide Protein Res 38: 131–138
Creutzfeldt W, Ebert R (1985) New developments in the in-cretin concept. Diabetologia 28:565–573
Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, Boyd III AE (1993) Cloning and functional expression of the human glucagon-like peptidel (GLP-1) receptor. Endocrinology 133:1907–1910
Fehmann HC, Göke R, Göke B (1992) Glucagon-like peptide1(7–37)/(7–36)amide is a new incretin. Mol Cell Endocrin 85:C39–C44
Fehmann HC, Habener JF (1991) Homologous desensitization of the insulinotropic glucagon-like peptide-1(7–37) receptor in insulinoma (HIT-T15) cells. Endocrinology 128:2880–2888
Fehmann HC, Habener JF (1992) Insulinotropic hormone glucagon-like peptide-1(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma 3TC1 cells. Endocrinology 130:159–166
Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V (1980) Continuous, clonal insulin-and somatostatin-secreting cell line established from a transplantable rat islet cell tumor. Proc Natl Acad Sci, USA 77:3519–3523
Göke R, Conlon JM (1988) Receptors for glucagon-like peptide-l(7–36)amide on rat insulinoma-derived cells. J Endocrinol 116:357–362
Göke R, Fehmann HC, Linn Th, Schmidt H, Krause M, Eng J, Göke B (1993b) Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide-1(7–36)amide receptor of insulin-secreting ß cells. J Biol Chem 268:19650–19655
Göke R, Oltmer B, Sheikh SP, Göke B (1992) Solubilization of active GLP-1(7–36)amide receptors from RINm5F plasma membranes. FEBS Lett 300:232–236
Göke R, Wagner B, Fehmann HC, Göke B (1993a) Glucosedependency of the insulin stimulatory effect of glucagonlike peptide-1(7–36)amide on the rat pancreas. Res Exp Med 193:97–103
Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic action of glucagon-like peptide 1(7–36)-amide. Diabetes 38:902–905
Lankat-Buttgereit B, Göke R, Fehmann HC, Richter G, Göke B (1994) Molecular cloning of a eDNA encoding for the GLP-1 receptor expressed in rat lung. Exp Clin Endocrinol 102:341–347
Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide-1-(737) in diabetic and nondiabetic subjects. Diabet Care 15:270–276
Nauck MA, Heimesaat MM, Q rskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory peptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307
Praz GA, Halban PA, Wollheim CB, Blondel B, Strauss JA. Reynold AE (1983) Regulation of immunoreactive insulin release from a rat cell line (RINm5F) Biochem J 210:345–352
Watanabe Y, Kawai K, Ohashi S, Yokota C, Suzuki S, Yamashita K (1994) Structure-activity of glucagon-like peptide-1(7–36)amide: insulinotropic activities in perfused rat pancreas, and receptor binding and cyclic AMP production in RINm5F cells. J Endocrinol 140:45–52
Cascieri MA, Saperstein R, Hayes NS, Green BG, Chicchi GG, Applebaum J, Bayne ML (1988) Serum half-live and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. Endocrinol 123:373–381
DeMeyts P (1994) The structural basis of insulin and insulin-like growth factor-I receptor binding and negative cooperativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 [Suppl 21:S135–S148
Dideriksen LH, Jorgensen LN, Drejer K (1992) Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41 (Suppl I):143A
Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes/ Metab Rev 8:259–286
Fantl WJ, Johnson DE, Williams LT (1993) Signalling by re- ceptor tyrosine kinases. Annu Rev Biochem 62:453–481
Froesch ER, Schmid C, Schwander J, Zapf J (1985) Actions of insulin-like growth factors. Ann Rev Physiol 47:443–467
Gammeltoft S, Drejer K (1991) Increased mitogenic potency of high affinity insulin analogues in mouse NIH 3T3 fibroblasts. J Cell Biol (Suppl 15B):54
Heinze E, Vetter U, Holl RW, Brenner RE (1995) Glibenclamide stimulates growth of human chondrocytes by IGF 1 dependent mechanisms. Exp Clin Endocrinol 103: 260–265
Moxley RT, Amer P, Moss A, Skottner A, Fox M, James D, Livingston JN (1990) Acute effects of insulin-like growth factor I and insulin on glucose metabolism in vivo. Am J Physiol; Endocrinol Metab 259:E561–E567
Nielsen FC, Haselbacher G, Christiansen J, Lake M, Gronborg M, Gammeltoft S (1993) Biosynthesis of 10 kDa and 7.5 kDa insulin-like growth factor II in a human rhabdomyosarcoma cell line. Mol Cell Endocrinol 93:87–95
Pierson RW, Temin HM (1972) The partial purification from calf serum of a fraction with multiplication-stimulating activity for chicken fibroblasts in the cell culture and with non-suppressible insulin-like activity. J Cell Physiol 79: 319–330
Rechler MM (1985) The nature and regulation of the receptors for insulin-like growth factors. Ann Rev Physiol 47: 425–442
Rinderknecht E, Humbel RE (1978 a) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769–2776
Rinderknecht E, Humbel RE (1978 b) Primary structure of human insulin-like growth factor II. FEBS Lett 89:283–286
Roth RA (1988) Structure of the receptor for insulin-like growth factor II: the puzzle amplified. Science 239: 1269–1271
Salamon EA, Luo J, Murphy LJ (1989) The effect of acute and chronic insulin administration on insulin-like growth factor expression in the pituitary-intact and hypophysectomized rat. Diabetologia 32:348–353
Salmon WD, Daughaday WH (1957) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vivo. J Lab Clin Med 49:825–836
Schäffer L, Kjeldsen T, Andersen AS, Wiberg FC, Larsen UD, Cara JF, Mirmira RG, Nakagawa SH, Tager HS (1993) Interaction of a hybrid insulin/insulin-like growth factor-I analog with chimeric insulin/type I insulin-like growth factor receptors. J Biol Chem 268:3044–3047
Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391
Schmitz F, Hartmann H, Stiimpel F, Creutzfeldt W (1991) In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologie 34:144–149
Schoenle E, Zapf J, Humbel RE, Froesch ER (1982) Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296:252–253
Schwander J, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: Dependence on growth hormone status. Endocrinol 113:297–305
Steinke J, Sirek A, Lauris V, Lukens FDW, Renold AE (1962) Measurement of small quantities of insulin-like activity with rat adipose tissue. III. Persistence of serum insulin-like activity after pancreatectomy. J Clin Invest 41: 1699–1707
Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212
Verspohl EJ, Maddux BA, Goldfine ID (1988) Insulin and insulin-like growth factor I regulate the same biological functions in HEP-G2 cells via their own specific receptors. J Clin Endocr Metab 67:169–174
Vikman K, Isgaard J, Edén S (1991) Growth hormone regulation of insulin-like growth factor-I mRNA in rat adipose tissue and isolated rat adipocytes. J Endocrinol 131: 139–145
Zapf J, Hauri C, Waldvogel M. Froesch ER (1986) Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77:1768–1775
Zapf J, Waldvogel M, Froesch ER (1975) Binding of non-suppressible insulin-like activity to human serum: Evidence for a carrier protein. Arch Biochem Biophys 168:638–645
Bänder A, Pfaff W, Schmidt FH, Stork H, Schröder HG (1969) Zur Pharmakologie von HB 419, einem neuen, stark wirksamen oralen Antidiabeticum. Arzneim Forsch/Drug Res 19:1363–1372
Fieller EC (1944) A fundamental formula in the statistics of biological assay, and some applications. Quart J Pharm Pharmacol 17:117–123
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Levene H (1960) Robust tests for equality of variances. In Olkin I, Ghury SG, Hoeffding W, Madow WG, Mann HB (eds.) Contributions to probability and statistics. Essays in honor of Harold Hotteling. Stanford University Press, Stanford, CA., pp 278–292
Miller RG (1966) Simultaneous statistical inference. McGraw-Hill Book Company, New York
Scheffé H (1959) The analysis of variance. J Wiley and Sons, Inc., New York
Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (Complete samples) Biometrika 52:591–611
Sidak Z (1967) Rectangular confidence regions for the means of multivariate normal distributions. J Am Statist Assoc 62:626–631
Bänder A, Pfaff W, Schmidt FH, Stork H, Schröder HG (1969) Zur Pharmakologie von HB 419, einem neuen, stark wirksamen oralen Antidiabeticum. Arzneim Forsch/Drug Res 19:1363–1372
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Gill AM, Yen TT (1991) Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 48:703–710
Root MA, Sigal MV, Anderson RC (1959) Pharmacology of 1(p-chlorobenzenesulfonyl)-3-n-propylurea (Chlorpropamide). Diabetes 8:7–13
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyll2,4-thiazolidinediones. Arzneim Forsch/Drug Res 40:37–42
Bänder A, Pfaff W, Schmidt FH, Stork H, Schröder HG (1969) Zur Pharmakologie von HB 419, einem neuen, stark wirksamen oralen Antidiabeticum. Arzneim Forsch/Drug Res 19:1363–1372
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Geisen K, Reisig E, Härtel D (1981) Kontinuierliche Blutglucosemessung und Infusion bei wachen, frei beweglichen Hunden. Continuous blood glucose monitoring and infusion in freely mobile dogs. Res Exp Med (Berl) 179: 103–111
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–223
Finegood DT, Bergman RN, Vranic A (1987) Estimation of endogenous glucose production during hyperinsulinemiceuglycemic glucose clamps. Comparison of unlabeled and labeled glucose infusates. Diabetes 36:914–924
Hirshman MF, Horton ES (1990) Glyburide increases insulin sensitivity and responsiveness in peripheral tissues of the rat as determined by the glucose clamp technique. Endocrinol 126:2407–2412
Kraegen EW, James DE, Bennett SP, Chishol DJ (1983) In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol 245:E1–E7
Kraegen EW, James DE, Jenkins AB, Chisholm DJ (1985) Dose-response curves for in vivo sensitivity in individual tissues in rats. Am J Physiol; Endocrin Metab 11:E353–E362
Lang CH (1992) Rates and tissue sites of noninsulin-and insulin-mediated glucose uptake in diabetic rats. Proc Soc Exp Biol Med 199:81–87
Lee MK, Miles PDG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM (1994) Metabolic effects of troglitazone on fructose-induced insulin resistance in rats. Diabetes 43: 1435–1439
Marfaing P, Ktorza A, Berthault MF, Predine J, Picon L, Penicaud L (1991). Effects of counterregulatory hormones on insulin-induced glucose utilization by individual tissues in rats. Diabete and Metabolisme (Paris) 17:55–60
Ohsawa I; Sato J, Oshida Y, Sato Y, Sakamoto N (1991) Effect of glimepiride on insulin action in peripheral tissues of the rat determined by the euglycemic clamp technique. J Japan Diab Soc 34:873–874
Smith D, Rossetti L, Ferrannini E, Johnson CM, Cobelli C, Toffolo G, Katz LD, DeFronzo RA (1987) In vivo glucose metabolism in the awake rat: Tracer and insulin clamp studies. Metabolism 36:1167–1174
Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatani K, Sasaki H (1993) Thiazolidin- ediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343–349
Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA (1990) In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056–1062
Colca JR (1995) Insulin sensitiser drugs in development for the treatment in diabetes. Expert Opin Invest Drugs 4: 27–29
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558
Gill AM, Yen TT (1991) Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 48:703–710
Hofmann C, Lorenz K, Colca JR (1991) Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinol 129:1915–1925
Hofmann CA. Edwards CW, Hillman RM, Colca JR (1992) Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 130:735–740
Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T Meguro K, Fujita T (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim Forsch/Drug Res 40:156–162
Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Häring H (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447–453
Kirsch DM, Bachmann W, Häring HU (1984) Ciglitazone reverses cAMP-induced post-insulin receptor resistance in rat adipocytes in vitro. FEBS Lett 176:49–54
Kobayashi M, Iwanshi M, Egawa K, Shigeta Y (1992) Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476–483
Lee MK, Miles PDG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM (1994) Metabolic effects of troglitazone on fructose-induced insulin resistance in rats. Diabetes 43: 1435–1439
Masuda K, Okamoto Y, Tuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Murano K, Inoue Y, Emoto M, Kaku K, Kaneko T (1994) CS-045, a new oral antidiabetic agent, stimulates fructose-2,6bisphosphate production in rat hepatocytes. Eur J Pharmacol 254:257–262
Murano K, Inoue Y, Emoto M, Kaku K, Kaneko T (1994) CS-045, a new oral antidiabetic agent, stimulates fructose-2,6bisphosphate production in rat hepatocytes. Eur J Pharmacol 254:257–262
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyll- 2,4-thiazolidinediones. Arzneim Forsch/Drug Res 40:37–42 Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto
M, Sekikawa A, Yamatani K, Sasaki H (1993) Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343–349
Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H (1993) Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75–80
Anderson E, Long JA (1947) The effect of hyperglycemia on insulin secretion as determined with the isolated rat pancreas in a perfusion apparatus. Endocrinology 40:92–97
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Grodsky GM, Batts AA, Bennett LL, Vicella C, McWilliams NB, Smith DF (1963) Effects of carbohydrates on secretion of insulin from isolated rat pancreas. Am J Physiol 205:638–644
Grodsky GM, Heldt A (1984) Method for the in vitro perfusion of the pancreas. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research. Vol. I.: Laboratory Methods, Part B, John Wiley and Sons, New York, pp 137–146
Ross BD (1972) Endocrine organs: Pancreas. In Ross BD: Perfusion Techniques in Biochemistry. A Laboratory Manual in the Use of Isolated Perfused Organs in Biochemical Experimentation. Clarendon Press, Oxford, pp 321–355
Fletcher DJ, Weir G (1984) Tissue culture of dispersed islet cells. In: Lamer J, Pohl StL (eds) Methods in Diabetes Research. Vol I: Laboratory Methods. Part A, John Wiley and Sons, New York, pp 167–173
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Idahl L4 (1972) A microperifusion device for pancreatic islets allowing concomitant recordings of intermediate metabolites and insulin release. Analyt Biochem 50:386–398
Kaiser N, Cerasi E (1991) Long term monolayer culture of adult rat islet of Langerhans. In: Greenstein B (ed) Neuroendocrine Research Methods. Vol I, Chapter 6, pp 131–147. Harwood Academic Publ
Lernmark A (1974) The preparation of, and studies on, free cell suspensions from mouse pancreatic islets. Diabetologia 10:431–438
Malaisse-Lagae F, Malaisse WJ (1984) Insulin release by pancreatic islets. In: Lamer J, Pohl StL (eds) Methods in Diabetes Research. Vol. I.: Laboratory Methods, Part B, John Wiley and Sons, New York, pp 147–152
McDaniel ML, Colca JR, Kotagal N (1984) Islet cell membrane isolation and characterization. In: Lamer J, Pohl StL (eds) Methods in Diabetes Research. Vol I: Laboratory Methods. Part A, John Wiley and Sons, New York, pp 153–166
Panten U, Ishida H, Schauder P, Frerichs H, Hasselblatt A (1977) A versatile microperifusion system. Anal Biochem 82:317–326
Pipeleers DG (1984) Islet cell purification. In: Lamer J, Pohl StL (eds) Methods in Diabetes Research. Vol. I.: Laboratory Methods, Part B, John Wiley and Sons, New York, pp 185–211
Schatz H, Maier V, Hinz M, Nierle C, Pfeiffer EF (1972) The effect of tolbutamide and glibenclamide on the incorporation of [’H] leucine and on the conversion of proinsulin to insulin in isolated pancreatic islets. FEBS Lett 26:237–240
Yoon JW, Bachurski CJ, Shin SY, Srinivasappa J, Rayfield EJ (1984) Simple method for human pancreatic ß cell cultures. In: Lamer J, Pohl StL (eds) Methods in Diabetes Research. Vol. 1.: Laboratory Methods, Part B, John Wiley and Sons, New York, pp 167–171
Bhatena SJ, Oie HK, Gazdar AF, Voyles NR, Wilkins SD, Recant L (1982) Insulin, glucagon, and somatostatin receptors on cultured cells and clones from rat islet cell tumor. Diabetes 31:521–531
Boyd III AE, Aguilar-Bryan L, Bryan J, Kunze DL, Moss L, Nelson DA, Rajan AS, Raef H, Xiang H, Yaney GC (1991) Sulfonylurea signal transduction. In. Bardin CW (ed) Proceedings of the 1990 Laurentian Hormone Conference. Rec Progr Horm Res 47:299–317
Chick WL, Warren S, Chute RN, Like AA, Lauris V, Kitchen KC (1977) A transplantable insulinoma in the rat. Proc Natl Acad Sci, USA 74:628–632
Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V (1980) Continuous, clonal, insulin-, and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc. Natl Acad Sci, USA 77:3519–3523
Geisen K, Hitzel V, Okonomopoulos R, Punter J, Weyer R, Summ HD (1985) Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics. Arzneim Forsch/Drug Res 35:707–712
Masuda K, Okamoto Y, Tuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Müller G, Hartz D, Punter J, Okonomopulos R, Kramer W (1994) Differential interaction of glimepiride and glibenclamide with the b-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1191:267–277
Praz GA, Halban PA, Wollheim CB, Blondel B, Strauss AJ, Renold AE (1983) Regulation of immunoreactive-insulin release from a rat cell line (RINm5F). Biochem J 210: 345–352
Santerre RF, Cook RA, Crisek RMD, Sharp JD, Schmidt RJ, William DC, Wilson CP (1981) Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic beta cells. Proc Natl Acad Sci USA 78:4339–4343
Geisen K, Hitzel V, Ôkonomopoulos R, Punter J, Weyer R, Summ HD (1985) Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics. Arzneim Forsch/Drug Res 35:707–712
Kaubisch N, Hammer R, Wollheim C, Renold AE, Offord R (1982) Specific receptors for sulfonylureas in brain and in a 13-cell tumor of the rat. Biochem Pharmacol 31:1171–1174
Müller G, Hartz D, Punter J, Okonomopulos R, Kramer W (1994) Differential interaction of glimepiride and glibenclamide with the 13-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1191:267–277
Aguilar-Bryan L, Nichols CG, Rajan AS, Parker Ch, Bryan J (1992) Co-expression of sulfonylurea receptors and KATP channels in hamster insulinoma tumor (HIT) cells. J Biol Chem 267:14934–14940
Angel I, Bidet S (1991) The binding site for [3H]glibenclamide in the rat cerebral cortex does nor recognize K-channel agonists or antagonists other than sulfonylureas. Fundam Clin Pharmacol 5:107–115
Ashcroft SJH, Ashcroft FM (1992) The sulfonylurea receptor. Biochem Biophys Acta 1175:45–59
Boyd III AE (1992) The role of ion channels in insulin secretion. J Cell Biochem 48:234–241
Gaines KL, Hamilton S, Boyd III AE (1988) Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem 263:2589–2592
Geisen K, Hitzel V, Ökonomopulos R, Punter J, Weyer R, Summ HD (1985) Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics. Arzneim Forsch/Drug Res 35:707–712
Masuda K, Okamoto Y, Tuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Müller G, Hartz D, Punter J, Okonomopulos R, Kramer W (1994) Differential interaction of glimepiride and glibenclamide with the 3-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1191:267–277
Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S (1989) Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 8:1217–1229
Panten U, Schwanstecher C, Schwanstecher M (1993) ATP-sensitive K+ channel: properties, occurrence, role in regulation of insulin secretion. In: Dickey BF, Birnbaumer L (eds) GTPases in Biology II, Handbook of Experimental Pharmacology Vol 108/I1, Springer Verlag Berlin, Heidelberg New York, pp 547–559
Schmid-Antomarchi H, DeWeille J, Fosset M, Lazdunski M (1987) The receptor for the antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. J Biol Chem 262:15840–15844
Schmid-Antomarchi H, deWeille J, Fosset M, Lazdunski M (1987) The antidiabetic sulfonylurea glibenclamide is a potent blocker of the ATP-modulated K+ channel in insulin secreting cells. Biochem Biophys Res Commun 146:21–25
Sugiura M, Sawada Y, Yamada Y, Nakamura K, Iga T (1992) Prediction of therapeutic doses of sulfonylureas based on receptor occupancy theory. Xenobiot Metab Dispos 7: 233–241
Aguilar-Bryan L, Nelson DA, Vu QA, Humphrey MB (1990) Photoaffinity labeling and partial purification of the b cell sulfonylurea receptor using a novel, biologically active glyburide analog. J Biol Chem 265:8218–8224
Bernardi H, Fosset M, Lazdunski M (1988) Characterization, purification, and affinity labeling of the brain [3Hlglibenclamide-binding protein, a putative neuronal ATP-regulated K* channel. Proc Natl Acad Sci USA 85:9816–9820
Boyd III AE, Aguilar-Bryan L, Bryan J, Kunze DL, Moss L, Nelson DA, Rajan AS, Raef H, Xiang H, Yaney GC (1991) Sulfonylurea signal transduction. Rec Progr Horm Res 47:299–317
Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hertz D, Summ HD (1994) Differential interaction of glimepiride and glibenclamide with the li-cell sulfonylurea receptor. II. Photoaffinity labeling. Biochem Biophys Acta 119:278–290
Kramer W, Oekonomopulos R, Pünter J, Summ HD (1988) Direct photolabeling of the putative sulfonylurea receptor in rat b-cell tumor membranes by [3H]glibenclamide. FEBS Lett 229:355–359
Wessel D, Flügge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138:141–143
Yip CC (1984) Photoaffinity probes for hormone receptor characterization. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research Vol I: Laboratory Methods, Part A, pp 3–14, John Wiley and Sons, New York
Boyd III AE, Aguilar-Bryan L, Bryan J, Kunze DL, Moss L, Nelson DA, Rajan AS, Raef H, Xiang H, Yaney GC (1991) Sulfonylurea signal transduction. Rec Progr Horm Res 47:299–317
Nicki I, Nicks JL, Ashcroft SJH (1990) The 13-cell glibenclamide receptor is an ADP-binding protein. Biochem J 268:713–718
Niki I, Kelly RP, Ashcroft SJH, Ashcroft FM (1989) ATP-sensitive K-channels in HIT T15 13-cells studied by patch-clamp methods, R6Rb efflux and glibenclamide binding. Pflügers Arch 415:47–55
Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M (1987) The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin secreting cells. J Biol Chem 262:15840–15844
Boyd III AE (1992) The role of ion channels in insulin secretion. J Cell Biochem 48:234–241
Boyd III AE, Aguilar-Bryan L, Bryan J, Kunze DL, Moss L, Nelson DA, Rajan AS, Raef H, Xiang H, Yaney GC (1991) Sulfonylurea signal transduction. Rec Progr Horm Res 47:299–317
deWeille J, Schmid-Antomarchi H, Fosset, M, Lazdunski M (1988) ATP-sensitive K+ channels that are blocked by hypoglycemia-inducing sulfonylureas in insulin-secreting cells are activated by galanin, a hyperglycemia-inducing hormone. Proc Natl Acad Sci, USA, 85:1312–1316
deWeille JR, Fossel M, Mourre C, Schmid-Antomarchi H, Bernardi H, Lazdunski M (1989) Pharmacology and regulation of ATP-sensitive K+ channels. Pflüger’s Arch 441 (Suppl 1) S80–S87
Dunne MJ, Illot MC, Petersen OH (1987) Interaction of diazoxide, tolbutamide and ATP on nucleotide-dependent K+ channels in an insulin-secreting cell line. J Membrane Biol 99:215–224
Hamill OP, Marty A, Neher E, Sakmann B, Sigworth RI (1981) Improved patch-clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pflüger’s Arch 391:85–100
Henquin JC, Meissner HP (1984) Effects of theophylline and dibutyryl cyclic adenosine monophosphate on the membrane potential of mouse pancreatic R-cells. J Physiol 351:595–612
Henquin JC, Schmeer W, Henquin M, Meissner HP (1984) Forskolin suppresses the slow cyclic variations of glucose-induced electrical activity in pancreatic ß cells. Biochem Biophys Res Commun 120:797–803
Henquin JC, Schmeer W, Henquin M, Meissner HP (1985) Effects of a calcium channel agonist on the electrical, ionic and secretory events in mouse pancreatic 13-cells. Biochem Biophys Res Commun 131:980–986
Kozlowski RZ, Sturgess NC, Hales CN, Ashford MU (1988) Inhibition of the ATP-K+ channel by glibenclamide in a rat insulinoma cell line. Br J Pharmacol 93:296P
Lindau M, Neher E (1988) Patch-clamp techniques for time-resolved capacitance measurements in single cells. Pflüger’s Arch 411:137–146
Meissner HP (1990) Membrane potential measurements in pancreatic 13 cells with intracellular microelectrodes. Meth Enzymol 192:235–246
Nelson TY, Gaines KL, Rajan AS, Berg M, Boyd III AE (1987) Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells. J Biol Chem 262:2606–2612
Niki I, Kelly RP, Ashcroft SJH, Ashroft FM (1989) ATP-sensitive K-channels in HIT T15 13-cells studied by patch-clamp methods, $“Rb efflux and glibenclamide binding. Pflügers Arch 415:47–55
Rajan AS, Aguilar-Bryan L, Nelson DA, Nichols CG, Wechsler SW, Lechago J, Bryan J (1993) Sulfonylurea receptors and ATP-sensitive K+ channels in clonal pancreatic 13 cells. Evidence for two high affinity sulfonylurea receptors. J Biol Chem 268:15221–15228
Rorsman P, Bokvist K, Ammälä C, Eliasson L, Renström E. Gäbel J (1994) Ion channels, electrical activity and insulin secretion. Diabete and Metabolisme (Paris) 20:138–145
Rorsman P, Trube G (1985) Glucose dependent K’ channels in pancreatic B-cells are regulated by intracellular ATP. Pflüger’s Arch 405:305–309
Rorsman P, Trube G (1986) Calcium and delayed potassium currents in mouse pancreatic 0-cells under voltage-clamp conditions. J Physiol 374:531–550
Schwanstecher C, Dickel C, Panten U (1992) Cytosolic nucleotides enhance the tolbutamide sensitivity of the ATP-dependent K+ channel in mouse pancreatic B cells by their combined actions at inhibitory and stimulatory receptors. Mol Pharmacol 41:480–486
Sturgess NC, Kozlowski RZ, Carrington CA, Hales CN, Ashford MU (1988) Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Phannacol 95:83–94
Trube G, Rorsman P, Ohno-Shosaku T (1986) Opposite effects of tolbutamide and diazoxide on the ATP-dependent K’ channel in mouse pancreatic 0-cells. Pflügers Arch 407:493–499
Wahl MA, Straub SG, Ammon HPT (1993) Vasoactive intestinal polypeptide-augmented insulin release: action on ionic fluxes and electrical activity of mouse islets. Diabetologia 36:920–925
Zünkler BJ, Lenzen S, Männer K, Panten U, Trube G (1988) Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells. NaunynSchmiedeberg’ s Arch Pharmacol 337:225–230
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Miller TB (1984) Use of liver perfusion for metabolic studies. In: Lamer J, Pohl SL (eds) Methods in Diabetes Research. Vol I: Laboratory Methods. Part A, John Wiley and Sons, New York, pp 143–151
Ross BD (1972) Perfusion techniques in biochemistry. A laboratory manual in the use of isolated perfused organs in biochemical experimentation. Clarendon Press, Oxford. pp 135–220
Sugano T, Suda K, Shimada M, Oshino N (1978) Biochemical and ultrastructural evaluation of isolated rat liver systems perfused with a haemoglobin-free medium. J Biochem 83: 995–1007
Berry MN, Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. A biochemical and fine structural study. J Cell Biol 43:506–520
Caro JF, Poulos J, Ittoop 0, Pories WJ, Flickinger EG, Sinha MK (1988) Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating and fetal rat liver. J Clin Invest 81:976–981
Chowdhury MH, Agius L (1987) Epidermal growth factor counteracts the glycogenic effect of insulin in parenchymal hepatocyte cultures. Biochem J 247:307–314
Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA (1990) In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056–1062
Czok R, Lamprecht W (1974) Pyruvate, phosphoenol-pyruvate and D-glycerate-2-phosphate. In: Bergmeyer HJ (ed) Methods of Enzymatic Analysis, Vol 3, Verlag Chemie Weinheim, Academic Press New York, London. pp 1446–1451
Forsayeth JR, Maddux BA, Goldfine IA (1986) Biosynthesis and processing of the human insulin receptor. Diabetes 35: 837–846
Forsayeth JR, Montemurro A, Maddux BA, DePirro R, Gold-fine ID (1988) Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. J Biol Chem 262:4134–4140
Fukuda H, Katsurada A, Iritani N (1992) Nutritional and hormonal regulation of mRNA levels of lipogenic enzymes in primary cultures of rat hepatocytes. J Biochem 111:25–30
Gliemann J (1965) Insulin-like activity of dilute human serum assayed by an isolated adipose cell method. Diabetes 14: 643–649
Gutmann I, Wahlefeld AM (1974) L-(+)-lactate determination with lactate dehydrogenase and NAD. In: Bergmeyer HJ (ed) Methods of Enzymatic Analysis, Vol 3, Verlag Chemie Weinheim, Academic Press New York, London. pp 1464–1468
Kobayashi M, Hotta N, Komori T, Haga T, Koh N, Sakakibara F, Sakamoto N (1991) Antigluconeo-genetic effect of a new potent sulfonylurea drug, Hoe 490, in isolated hepatocytes from normal, fasted rats. J Japan Diab Soc 34: 767–774
Mellanby J, Williamson DH (1974) Acetoactetate. In: Bergmeyer HJ (ed) Methods of Enzymatic Analysis, Vol 4, Verlag Chemie Weinheim, Academic Press New York, London. pp 1840–1843
Podskalny JM, Takeda S, Silverman RE, Tran D, Carpentier JL, Orci L, Gorden P (1985) Insulin receptors and bioresponses in a human liver cell line (Hep G-2). Eur J Biochem 150:401–407
Seglen PO (1976) Preparation of isolated rat liver cells. In: Prescott DM (ed) Methods in Cell Biology, Vol XIII, Academic Press, New York, pp 29–83
Verspohl EJ, Maddux BA, Goldfine IA (1988) Insulin and insulin-like growth factor regulate the same biological functions in Hep G2 cells via their own specific receptors. J Clin Endocrin Metab 67:169–174
Wade DP, Knight BL, Soutar AK (1988) Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells. Insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. Eur J Biochem 174:213–218
Williamson DH, Mellanby J (1974) D-(-)-3-hydroxybutyrate. In: Bergmeyer HJ (ed) Methods of Enzymatic Analysis, Vol 4, Verlag Chemie Weinheim, Academic Press New York, London. pp 1836–1839
Aoki M, Kaku K, Inoue H, Matsutani A, Kaneko T (1992) Tolbutamide inhibits cAMP-dependent phosphorylation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Diabetes 41:334–338
Furuya E, Uyeda K (1980) An activation factor of liver phos- phofructokinase. Proc Natl Acad Sci USA 77:5861–5864
Gabbay RA, Lardy HA (1987) Insulin inhibition of hepatic cAMP-dependent protein kinase: Decreased affinity of protein kinase for cAMP and possible differential regulation of interchain sites 1 and 2. Proc Nat] Acad Sci USA 84:2218–2222
Hatao K, Kaku K, Matsuda M, Tsuchiya M, Kaneko T (1985) Sulfonylurea stimulates liver fructose-2,6-bisphosphate formation in proportion to its hypoglycemic action. Diab Res Clin Pract 1:49–53
Kaku K, Matsuda M, Matsutani A, Kaneko T (1986) Effect of tolbutamide on fructose-6-phosphate-2-kinase and fructose2,6-bisphosphatase in rat liver. Biochem Biophys Res Commun 139:687–692
Mori K, Kaku K, Inoue H, Aoki M, Marsutani A, Kaneko T (1992) Effects of tolbutamide on fructose-2,6-bisphosphate formation and ketogenesis in hepatocytes from diabetic rats. Metabolism 41:706–710
Murano K, Inoue Y, Emoto M, Kaku K, Kaneko T (1994) CS-045, a new oral antidiabetic agent, stimulates fructose-2,6bisphosphate production in rat hepatocytes. Eur J Pharmacol 254:257–262
Pilkis SJ, El-Maghrabi MR (1988) Hormonal regulation of hepatic gluconeogenesis and glycolysis. Ann Rev Biochem 57:755–783
Richards CS, Uyeda K (1982) The effect of insulin and glucose on fructose-2,6-P2 in hepatocytes. Biochem Biophys Res Commun 109:394–401
Van Schaftingen E (1993) Glycolysis revisited. Diabetologia 36:581–588
Vaulont S, Kahn A (1994) Transcriptional control of metabolic regulation genes by carbohydrates. FASEB J 8:28–35
Daniels EL, Lewis SB (1982) Acute tolbutamide administration alone and combined with insulin enhances glucose uptake in the perfused rat hindlimb. Endocrinology 110:1840–1842
Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch/Drug Res 38:1120–1130
Ruderman NB, Houghton CRS, Hems R (1971) Evaluation of the isolated perfused rat hindquarter for the study of muscle metabolism. Biochem J 124:639–651
Bahr M, von Holtey M, Müller G, Eckel J (1995) Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 136:2547–2553
Calderhead DM, Kitagawa K, Lienhard GE, Gould GW (1990) Translocation of the brain-type glucose transporter largely accounts for insulin stimulation of glucose transport in BC3H-1 myocytes. Biochem J 269:597–601
Cooper DR, Vila MC, Watson JE, Nair G, Pollet RJ, Standaert M, Farese RV (1990) Sulfonylurea-stimulated glucose transport association with diacylglycerol-like activation of protein kinase C in BC3H1 myocytes. Diabetes 39:1399–1407
Davidson MB, Molnar IG, Furman A, Yamaguchi D (1991) Glyburide-stimulated glucose transport in cultured muscle cells via protein kinase C-mediated pathway requiring new protein synthesis Diabetes 40:1531–1538
Eckel J, Asskamp B, Reinauer H (1991) Induction of insulin resistance in primary cultured adult cardiac myocytes. Endocrinology 129:345–352
Eckel J, Pandalis G, Reinauer H (1983) Insulin action on the glucose transport system in isolated cardiocytes from adult rat. Biochem J 212:385–392
Kayalar C, Wong WT, Hendrickson L (1990) Differentiation of BC3H1 and primary skeletal muscle cells and the activity of their endogenous insulin-degrading enzyme are inhibited by the same metalloendoprotease inhibitors. J Cell Biochem 44:137–151
Klip A, Marette A (1992) Acute and chronic signals controlling glucose transport in skeletal muscle. J Cell Biochem 48:51–60
Klip A, Ramlal RJ (1987) T, Douen AG, Burdett E, Young D, Cartee GD, Holloszy JO (1988) Insulin-induced decrease in 5’-nucleotidase activity in skeletal muscle membranes. FEBS Lett 238:419–423
McCusker RH, Clemmons DR (1994) Effects of cytokines on insulin-like growth factor-binding protein secretion by muscle cells in vitro. Endocrinology 134:2095–2102
McMahon DK, Anderson PAW, Nassar R, Bunting JB, Saba Z, Oakeley AE, Malouf NN (1994) C2C12cells: biophysical, biochemical, and immunocytochemical properties. Am J Physiol Cell Physiol 266:C1795–C1802
Mitsumoto Y, Burdett E, Grant A, Klip A (1991) Differential expression of the GLUT1 and GLUT4 glucose transporters during differentiation of L6 muscle cells. Biochem Biophys Res Commun 175:652–659
Munson R, Calswell KL, Glaser L (1982) Multiple control for the synthesis of muscle-specific proteins in BC3H1 cells. J Cell Biol 92:350–356
Pardrige WM, Davidson MB, Casanello-Ertl D (1978) Glucose and amino acid metabolism in an established cell line of skeletal muscle cells. J Cell Physiol 96:309–317
Rogers BJ, Standaert ML, Pollet (1987) Direct effects of sulfonylurea agents on glucose transport in the BC3H1 myocyte. Diabetes 39:1292–1296
Rosen KM, Wentworth BM, Rosenthal N, Villa-Komaroff L (1993) Specific, temporally regulated expression of the insulin-like growth factor II gene during muscle cell differentiation. Endocrinology 133:474–481
Saltiel AR, Fox JA, Sherline P, Cuatrecasas P (1986) Insulin-stimulated hydrolysis of a novel glycolipid generates modulators of cAMP phosphodiesterase. Science 233:967–972
Sarabia V, Lam L, Burdett E, Leiter LA, Klip A (1992) Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest 90: 1386–1395
Schubert D, Harris AJ, Devine CE, Heinemann S (1974) Characterization of a unique muscle cell line. J Cell Biol 61: 398–413
Standaert ML, Shimmel SD, Pollet RJ (1984) The development of insulin receptors and responses in the differentiating nonfusing muscle cell line BC3H1. J Biol Chem 259: 2337–2345
Wang PH, Beguinot F, Smith RJ (1987) Augmentation of the effects of insulin and insulin-like growth factors I and II on glucose uptake in cultured rat skeletal muscle cells by sulfonylureas. Diabetologia 30:797–803
Wang PH, Moller D, Flier JS, Nayak RC, Smith RJ (1989) Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 skeletal muscle cells. J Clin Invest 84:62–67
Yaffe D (1986) Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 61:477–483
Yaffe D, Saxel O (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, Lond. 270:725–727
Bischoff H (1991) Wirkung von Acarbose auf diabetische Spätkomplikationen und Risikofaktoren — Neue tierexperimentelle Ergebnisse. Akt Endokrin Stoffw 12:25–32
Bischoff H (1994) Pharmacology of a-glucosidase inhibition Eur J Clin Invest 24, Suppl 3:3–10
Bischoff H, Puls W, Krause HP, Schutt H, Thomas G (1985) Pharmacological properties of the novel glucosidase inhibitors BAY M1099 (Miglitol) and BAY 0 1248. Diab Res Clin Pract Suppl 1:S53
Lembcke B, Lamberts R, Creutzfeldt W (1991) Lysosomal storage of glycogen as a sequel of a-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe’s disease (glycogenosis type II). Res Exp Med 191:389–404
Shainkin R, Birk Y (1970) a-Amylase inhibitors from wheat. Isolation and characterization. Biochim Biophys Acta 221:502–513
Rick W, Stegbauer HP (1970) cc-Amylase. Messung der reduzierenden Gruppen. In: Bergmeyer H (ed) Methoden der enzymatischen Analyse, Vol II, 2nd ed., pp 848–853
Dahlqvist A (1964) Method for assay of intestinal disaccharidases. Anal Biochem 7:18–25
Matsuo T, Odaka H, Ikeda H (1992) Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55, Suppl 1:3145–317S
Madar Z (1983) Demonstration of amino acid and glucose transport in chicken small intestine everted sac as a student laboratory exercise. Biochem Educ 1 L:9–1 1
Madar Z, Omusky Z (1991) Inhibition of intestinal etglucosidase activity and postprandial hyperglycemia by etglucosidase inhibitors in fa/fa rats. Nutr Res 11:1035–1046
Lembcke B, Fölsch UR, Creutzfeldt W (1985) Effect of 1desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 31:120–127
Glick Z, Bray GA (1983) Effects of acarbose on food intake, body weight and fat depots in lean and obese rats. Pharmacol Biochem Behav 19:71–78
Ho RS, Aranda CG (1979) The influence of 2,2-dimethyl-l-(4methylphenyl)-1-propanone (SaH 50–283) on food efficiency in rats. Arch Int Pharmacodyn 237:98–109
Ikeda H, Odaka H, Matsuo T (1991) Effect of a disaccharidase inhibitor, AO-128, on a high sucrose-diet-induced hyperglycemia in female Wistar fatty rats. Jpn Pharmacol Ther 19:155–150
Le Marchand-Brustel Y, Rochet N, Grémeaux T, Marot I, Van Obberghen E (1990) Effect of an a-glycosidase inhibitor on experimentally induced obesity in mice. Diabetologia 33: 24–30
Madar Z, Omusky Z (1991) Inhibition of intestinal aglucosidase activity and postprandial hyperglycemia by aglucosidase inhibitors in fa/fa rats. Nutr Res 11:1035–1046
Matsuo T, Odaka H, Ikeda H (1992) Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55, Suppl 1:314S–317S
Okada H, Shino A, Ikeda H, Matsuo T (1992) Anti-obesity and antidiabetic actions of a new potent disaccharidase inhibitor in genetically obese-diabetic mice, KKAr. J Nut Sci Vitaminol 38:27–37
Puls W, Keup U (1973) Influence of an a-amylase inhibitor (BAY d 7791) on blood glucose, serum insulin and NEFA in starch loading tests in rats, dogs and man. Diabetologia 9:97–101
Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F (1977) Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwiss 64:536–537
Takami K, Okada H, Tsukuda R, Matsuo T (1991) Antidiabetic actions of a disaccharidase inhibitor, AO-128, in spontaneously diabetic (GK) rats. Jpn J Pharmacol Ther 19: 161–171
Cameron NE, Cotter MA, Robertson S (1989) Contractile properties of cardiac papillary muscle in streptozotocindiabetic rats and the effects of aldose reductase inhibition. Diabetologia 32:365–370
Clements RS (1979) Diabetic neuropathy — new concepts in its etiology. Diabetes 28:604–611
Geisen K, Utz R, Grötsch H, Lang HJ, Nimmesgern H (1994) Sorbitol-accumulating pyrimidine derivatives. Arzneim Forsch/Drug Res 44:1032–1043
Kador PF, Robison WG, Kinoshita JH (1985) The pharmacology of aldose reductase inhibitors. Ann Rev Pharmacol Toxicol 25:691–714
Pugliese G, Tilton RG, Speedy A, Chang K, Province MA, Kilo C, Williamson JR (1990) Vascular filtration function in galactose-fed versus diabetic rats: the role of polyol pathway activity. Metabolism 39:690–697
Rathbun WB (1980) Biochemistry of the lens and cataractogenesis: Current concepts. Symposium on Ophthalmology. Veterinary Clinics of North America: Small Animal Practice 10:377–398
Sarges R, Oates PJ (1993) Aldose reductase inhibitors: Recent developments. Progr Drug Res 40:99–161
Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, Williamson JR (1989) Prevention of hemodynamic and vascular filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38:1258–1270
Tilton RG, Chang K, Weigel C, Eades D, Sherman WR, Kilo C, Williamson JR (1988) Increased ocular blood flow and ‘25I-albumin permeation in galactose-fed rats: Inhibition by sorbinil. Invest Ophthalm Vis Sci 29:861–868
van Heyningen R (1959) Formation of polyols by the lens of the rat with “sugar” cataract. Nature 184:194–195
Williamson JR, Chang K, Tilton RG, Prater C, Jeffrey JR, Weigel C, Sherman WR, Eades DM, Kilo C (1987) Increased vascular permeability in spontaneously diabetic BB/W rats and rats with mild versus severe streptozotocininduced diabetes. Diabetes 36:813–821
Yue DK, Hanwell MA, Satchell PM, Tuftle JR (1982) The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 31:789–794
Billon F, Delchambre Ch, Cloarec A, Sartori E, Teulon JM (1990) Aldose reductase inhibition by 2,4-oxo and thioxo derivates of 1,2,3,4-tetrahydroquinazoline. Eur J Med Chem 25:121–126
Hayman S, Kinoshita JH (1965) Isolation and properties of lens aldose reductase. J Biol Chem 240:877–882
Jacobson M, Sharma YR, Cotlier E, Hollander JD (1983) Diabetic complications in lens and nerve and their prevention by Sulindac or Sorbinil: Two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci 24:1426–1429
Peterson MJ, Sarges R, Aldinger CE, MacDonald DP (1979) CP 45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 28:456–461
Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y (1984) Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 229:226–230
Terashima H, Tanaka M, Motoishi M, Yamamoto R, Hama K, Okegawa T, Kawasaki A (1988) Biochemical studies of a new aldose reductase inhibitor, ONO-2235. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 82–87
Varma S, Kinoshita JH (1976) Inhibition of lens aldose reductase by flavonoids — their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 25:2505–2513
Calcutt NA, Mizisin AP, Kalichman MW (1994) Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. Eur J Pharmacol 251:27–33
Cameron NE, Cotter MA, Low AP (1991) Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 261 EI-E8
Cameron NE, Cotter MA, Robertson S (1989) The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Quart J Exp Physiol 74:917–926
Cameron NE, Leonard MB, Ross IS, Withing PH (1986) The effects of Sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia 29:168–174
Carrington AL, Ettlinger CB, Calcutt NA, Tomlinson DR (1991) Aldose reductase inhibition with imirestat—effects on impulse conduction and insulin-stimulation of Na’/K’adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia 34:397–401
Gillon KRW, Hawthorne JN, Tomlinson DR (1983) Myoinositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibition. Diabetologia 25:365–371
Greene DA, Chakrabarti S, Lattimer SA, Sima AAF (1987) Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibres in the insulin-deficient spontaneously diabetic Bio-breeding rat. J Clin Invest 79:1479–1485
Greene DA, DeJesus PV, Winegrad AI (1975) Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55:1326–1336
Hirata Y, Fujimori S, Okada K (1988) Effect of a new aldose reductase inhibitor, 8’-chloro-2’,3’-dihydrospiro[pyrrolidine-3,6’(5 ‘H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5’trione (ADN-138), on delayed motor conduction velocity in streptozotocin-diabetic rats. Metabolism 37:159–163
Hotta N, Sigimura K, Kakuta H, Fukasawa H, Kimura M, Koh N, Matsumae H, Kitoh R, Sakamoto N (1988) Effects of a fructose-rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocintreated rats. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 505–511
Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M (1983) Effect of a new aldose reductase inhibitor, (E)-3-Carboxymethyl-5[(2E)-methyl-3-phenylpropylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 24:290–292
Miyoshi T, Goto I (1973) Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes. Electroencephalogr Clin Neurophysiol 35:125–131
Price DE, Airey CM, Alani SM, Wales JK (1988) Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes. Diabetes 37:969–973
Schmidt RE, Plurad SB, Coleman BD, Williamson JR, Tilton RG (1991) Effects of sorbinil, dietary myo-inositol supplementation, and insulin on resolution of neuroaxonal dystrophy in mesenteric nerves of streptozotocin-induced diabetic rats. Diabetes 40:573–582
Sharma AK, Thomas PK (1974) Peripheral nerve structure and function in experimental diabetes. J Neurol Sci 23:1–15
Sima AAF, Prashar A, Zhang WX, Chakrabarti S, Greene DA (1990) Preventive effect of long-term aldose reductase inhibition (Ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. J Clin Invest. 85:1410–1420
Stribling D, Mirrlees DJ, Harrison HE, Earl DCN, (1985) Properties of ICI 128,436, a novel aldose reductase inhibitor and its effects on diabetic complications in the rat. Metabolism 34:336–344
Calcutt NA, Mizisin AP, Kalichman MW (1994) Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. Eur J Pharmacol 251:27–33
Engerman RL (1989) Pathogenesis of diabetic retinopathy. Diabetes 38:1203–1206
Funada M, Okamoto I, Fujinaga Y, Yamana T (1987) Effects of aldose reductase inhibitor (M79175) on ERG oscillatory potential abnormalities in streptozotocin fructose-induced diabetes in rats. Jpn J Ophthalm 31:305–314
Hotta N, Kakuta H, Fukasawa H, Koh N, Matsumae H, Kimura M, Sakamoto N (1988) Prevention of diabetic neuropathy by an aldose reductase inhibitor in fructose-fed streptomycin-diabetic rats. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 311–318
Kozak WM, Marker NA, Elmer KK (1986) Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats. Docum Ophthalm 64:355–377
Kuwabara T, Cogan DG (1960) Studies on retinal vascular patterns. Arch Ophthalm 64:904–911
Lightman S, Rechthand E, Terubayashi H, Palestine A, Rapoport A, Kador P (1987) Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors. Diabetes 36:1271–1275
Nagata M, Robison WG (1988) Basement membrane thickening in retina and muscle of animal models of diabetes. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica. Amsterdam, pp 276–285.
Segawa M, Hirata Y, Fujimori S, Okada K (1988) The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism 37:454–460
Segawa M, Takahashi N, Namiki H, Masuzawa K (1988) Electrophysiological abnormalities and polyol accumulation in retinas of diabetic and galactosemic rats. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 306–310
Akagi Y, Tasaka H, Terubayashi H, Kador PF, Kinoshita JH (1988) Aldose reductase localization in rat sugar cataract. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 170–181
Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu Y, Yamaguchi I (1991) Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism 40:77–87
Dvornik D, Simard-Duquesne, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO (1973) Polyol accumulation in galactosemic and diabetic rats: Control by an aldose reductase inhibitor. Science 182:1146–1148
Griffin BW, Chandler ML, DeSantis L (1984) Prevention of diabetic cataract and neuropathy in rats by two new aldose reductase inhibitors. Invest Ophthal Vis Sci 25:136
Hockwin O, Wegener A, Sisk DR, Dohrmann B, Kruse M (1985) Efficacy of AL-1576 in preventing naphthalene cataract in three rat strains. Slit lamp and Scheimpflug photographic study. Lens Res 2:321–335
Kinoshita JH (1965) Cataracts in galactosemia. Invest Ophthal 4:786–799
Kinoshita JH (1974) Mechanisms initiating cataract formation. Invest Ophthal 13:713–724
Kinoshita JH, Fukushi S, Kador P, Merola LO (1979) Aldose reductase in diabetic complications of the eye. Metabolism 28 (Suppl 1):462–469
Müller P, Hockwin O, Ohrloff C (1985) Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts. Ophthal Res 17:115–119
Nishimura C, Akagi Y, Robison WG, Kador PF, Kinoshita JH (1988) Increased aldose reductase in galactosemic lens. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 182–188
Pirie A, van Heyningen R (1964) Effect of diabetes on the content of sorbitol, glucose, fructose and inositol in the human lens. Exp Eye Res 3:124–131
van Heyningen R (1959) Formation of polyols by the lens of the rat with “sugar” cataract. Nature 184:194–195
Varma SD. Kinoshita JH (1976) Inhibition of lens aldose reductase by flavonoids - their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 25:2505–2513
Wegener A, Hockwin 0 (1991) Benefit/risk assessment of ophthalmic anti-infectives. Chibret Intern J Ophthalmol 8: 43–45
Billon F, Delchambre Ch, Cloarec A, Sartori E, Teulon JM (1990) Aldose reductase inhibition by 2,4-oxo and thioxo derivates of 1,2,3,4-tetrahydroquinazoline. Eur J Med Chem 25:121–126
Gonzales AM, Sochor M, Hothersall JS, McLean P (1986) Effect of aldose reductase inhibitor (sorbinil) on integration of polyol pathway, pentose phosphate pathway and glycolytic route in diabetic rat lens. Diabetes 35:1200–1205
Griffin BW, McNatt LG, Chandler ML, York BM (1987) Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats. Metabolism 36:486–490
Hockwin 0 (1989) Die Scheimpflug-Photographie der Linse. Fortschr Ophthalmol 86:304–311
Hu TS, Datiles M, Kinoshita JH (1983) Reversal of galactose cataract with sorbinil in rats. Invest Ophthalmol Vis Sci 24:640–644
Keller HW, Koch HR (1978) Experimental arabinose cataracts. Interdiscipl Topics Gerontol 12:141–146
Lee SM; Schade SZ, Doughty CC (1985) Aldose reductase, NADPH, and NADP+ in normal, galactose-fed and diabetic rat lens. Biochem Biophys Acta 841:247–253
Müller P, Hockwin 0, Ohrloff C (1985) Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts. Ophthal Res 17:115–119
Naeser et al (1988) Sorbitol metabolism in the retina, optic nerve, and sural nerve of diabetic rats treated with an aldose reductase inhibitor
Sekiguchi M, Watanabe K, Eto M, Iwashima Y, Morikawa A, Oshima E, Chonan N, Takebe R, Ishii K (1988) The effect of the aldose reductase inhibitor ON0–2235 on the polyol pathway in diabetic Chinese hamsters. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds) Polyol pathway and its role in diabetic complications. Excerpta Medica, Amsterdam, pp 88–92
Varma S, Kinoshita JH (1976) Inhibition of lens aldose reductase by flavonoids — their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 25:2505–2513
Hockwin O, Wegener A, Sisk DR, Dohrmann B, Kruse M (1985) Efficacy of AL-1576 in preventing naphthalene cataract in three rat strains. Slit lamp an Scheimpflug photographic study. Lens Res 2:321–335
Hockwin O (1989) Die Scheimpflug-Photographie der Linse. Fortschr Ophthalmol 86:304–311
Wegener A, Hockwin O (1991) Benefit/risk assessment of ophthalmic anti-infectives. Chibret Intern J Ophthalmol 8: 43–45
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Vogel, H.G., Vogel, W.H. (1997). Antidiabetic activity. In: Vogel, H.G., Vogel, W.H. (eds) Drug Discovery and Evaluation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03333-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-03333-3_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-03335-7
Online ISBN: 978-3-662-03333-3
eBook Packages: Springer Book Archive